[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fSPy1eSy7xDOQ0E_MouKOaLyk-OPn5qsRyvdA2pF7cMs":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":50,"rows":57},"Ludwig-Maximilians - University of Munich",[4],221,false,26,21,81434,6,151,[14,17,20,23,25,28,30,32],{"name":15,"count":16},"Depression",12,{"name":18,"count":19},"Depressive Disorder",10,{"name":21,"count":22},"Depression in Adolescence",9,{"name":24,"count":11},"Schizophrenia",{"name":26,"count":27},"Quality of Life",5,{"name":29,"count":27},"Ischemic Stroke",{"name":31,"count":27},"Healthy",{"name":33,"count":27},"Metastatic Colorectal Cancer",[35,40,45],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT04034173","Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation","2024-08-01","Panitumumab",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT04224636","Atezolizumab\u002FBevacizumab Followed by On-demand TACE or Initial Synchronous Treatment With TACE and Atezolizumab\u002FBevacizumab","2025-03-01","Atezolizumab Injection, Bevacizumab",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT07586150","Personalized Pharmaco-Lifestyle Interventions for Severe Mental Illnesses (LIFETRAIN)","2030-07","Semaglutide",[51,52,53,54,55,56],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[58,164,211,245,263,285,309,348,403,429,455,473,491,516,534,552,580,598,623,645,670,693,731,761,798,826,844,862,880,905,933,951,977,1004,1031,1058,1083,1101,1119,1137,1155,1173,1191,1209,1235,1262,1280,1298,1326,1344,1370,1396,1414,1438,1456,1484,1502,1520,1538,1556,1574,1604,1634,1661,1679,1697,1722,1740,1763,1781,1799,1817,1845,1863,1881,1908,1926,1950,1968,1986,2016,2040,2063,2088,2111,2137,2155,2173,2191,2219,2237,2255,2273,2297,2319,2360,2396,2419,2437,2465,2483,2501,2519,2537,2555,2573,2599,2617,2640,2665,2689,2712,2737,2764,2782,2813,2831,2849,2867,2885,2903,2921,2939,2963],{"intervention":59,"totalTrials":60,"cells":61},"Irinotecan",7,{"EARLY_PHASE1":62,"PHASE1":65,"PHASE2":67,"PHASE3":134,"PHASE4":160,"NA":162},{"trials":63,"activeCount":64},[],0,{"trials":66,"activeCount":64},[],{"trials":68,"activeCount":133,"soonestReadout":38},[69,86,99,112,120],{"nctId":70,"briefTitle":71,"status":72,"phases":73,"primaryCompletion":74,"completion":75,"start":76,"enrollment":77,"conditions":78,"interventions":80},"NCT01729481","Gemcitabine Plus Erlotinib in RASH-positive Patients With Metastatic Pancreatic Cancer","UNKNOWN",[53],"2015-07","2017-12","2012-07",150,[79],"Metastatic Pancreatic Adenocarcinoma",[81,82,83,84,59,85],"Gemcitabine","Erlotinib","Oxaliplatin","Folinic Acid","5-FU",{"nctId":87,"briefTitle":88,"status":72,"phases":89,"primaryCompletion":90,"completion":91,"start":92,"enrollment":93,"conditions":94,"interventions":95},"NCT04034459","FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC",[53],"2023-11-01","2023-12-31","2016-11-25",109,[33],[96,59,97,83,85,98],"Bevacizumab","Folinic acid","Cetuximab",{"nctId":100,"briefTitle":101,"status":102,"phases":103,"primaryCompletion":104,"completion":105,"start":106,"enrollment":107,"conditions":108,"interventions":110},"NCT05217069","FOLFIRI + Cetuximab + Avelumab RAS Wild-type CRC","COMPLETED",[53],"2023-09-01","2023-10-18","2019-09-27",57,[109],"Treatment Related Cancer",[85,84,59,98,111],"Avelumab",{"nctId":36,"briefTitle":37,"status":113,"phases":114,"primaryCompletion":38,"completion":115,"start":116,"enrollment":117,"conditions":118,"interventions":119},"NOT_YET_RECRUITING",[53],"2026-08-01","2019-08-01",120,[109],[39,59,97,85],{"nctId":121,"briefTitle":122,"status":102,"phases":123,"completion":124,"start":125,"enrollment":126,"conditions":127,"interventions":128},"NCT00254137","Cap\u002FIri Plus Cetuximab Compared to Cap\u002Fox Plus Cetuximab in Patients With Metastatic Colorectal Cancer.",[53],"2006-11","2004-09",92,[33],[129,130,131,132],"capecitabine","irinotecan","oxaliplatin","cetuximab",1,{"trials":135,"activeCount":64},[136,148],{"nctId":137,"briefTitle":138,"status":72,"phases":139,"primaryCompletion":140,"completion":141,"start":142,"enrollment":143,"conditions":144,"interventions":146},"NCT01249638","Cap+Bev vs Cap+Iri+Bev 1st-line Therapy in mCRC",[54],"2013-12","2016-12","2010-12",516,[145],"Colorectal Cancer Metastatic",[147,96,147,59,96],"Capecitabine",{"nctId":149,"briefTitle":150,"status":102,"phases":151,"primaryCompletion":152,"completion":152,"start":153,"enrollment":154,"conditions":155,"interventions":156},"NCT02934529","Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab",[54],"2025-01-30","2015-03",673,[33],[59,84,85,85,98,96,147,157,158,159],"regorafenib","Irinotecan 125mg","Cetuximab wkly",{"trials":161,"activeCount":64},[],{"trials":163,"activeCount":64},[],{"intervention":85,"totalTrials":11,"cells":165},{"EARLY_PHASE1":166,"PHASE1":168,"PHASE2":170,"PHASE3":201,"PHASE4":207,"NA":209},{"trials":167,"activeCount":64},[],{"trials":169,"activeCount":64},[],{"trials":171,"activeCount":133,"soonestReadout":38},[172,176,189,193,197],{"nctId":70,"briefTitle":71,"status":72,"phases":173,"primaryCompletion":74,"completion":75,"start":76,"enrollment":77,"conditions":174,"interventions":175},[53],[79],[81,82,83,84,59,85],{"nctId":177,"briefTitle":178,"status":72,"phases":179,"primaryCompletion":180,"completion":181,"start":182,"enrollment":183,"conditions":184,"interventions":186},"NCT03487016","First-line Therapy in Metastatic PDAC",[53],"2022-07-01","2023-07","2019-02-15",270,[185],"Metastatic Pancreatic Cancer",[81,187,85,188,83],"Nab-paclitaxel","Irinotecan Liposomal",{"nctId":87,"briefTitle":88,"status":72,"phases":190,"primaryCompletion":90,"completion":91,"start":92,"enrollment":93,"conditions":191,"interventions":192},[53],[33],[96,59,97,83,85,98],{"nctId":100,"briefTitle":101,"status":102,"phases":194,"primaryCompletion":104,"completion":105,"start":106,"enrollment":107,"conditions":195,"interventions":196},[53],[109],[85,84,59,98,111],{"nctId":36,"briefTitle":37,"status":113,"phases":198,"primaryCompletion":38,"completion":115,"start":116,"enrollment":117,"conditions":199,"interventions":200},[53],[109],[39,59,97,85],{"trials":202,"activeCount":64},[203],{"nctId":149,"briefTitle":150,"status":102,"phases":204,"primaryCompletion":152,"completion":152,"start":153,"enrollment":154,"conditions":205,"interventions":206},[54],[33],[59,84,85,85,98,96,147,157,158,159],{"trials":208,"activeCount":64},[],{"trials":210,"activeCount":64},[],{"intervention":84,"totalTrials":27,"cells":212},{"EARLY_PHASE1":213,"PHASE1":215,"PHASE2":217,"PHASE3":235,"PHASE4":241,"NA":243},{"trials":214,"activeCount":64},[],{"trials":216,"activeCount":64},[],{"trials":218,"activeCount":133,"soonestReadout":38},[219,223,227,231],{"nctId":70,"briefTitle":71,"status":72,"phases":220,"primaryCompletion":74,"completion":75,"start":76,"enrollment":77,"conditions":221,"interventions":222},[53],[79],[81,82,83,84,59,85],{"nctId":87,"briefTitle":88,"status":72,"phases":224,"primaryCompletion":90,"completion":91,"start":92,"enrollment":93,"conditions":225,"interventions":226},[53],[33],[96,59,97,83,85,98],{"nctId":100,"briefTitle":101,"status":102,"phases":228,"primaryCompletion":104,"completion":105,"start":106,"enrollment":107,"conditions":229,"interventions":230},[53],[109],[85,84,59,98,111],{"nctId":36,"briefTitle":37,"status":113,"phases":232,"primaryCompletion":38,"completion":115,"start":116,"enrollment":117,"conditions":233,"interventions":234},[53],[109],[39,59,97,85],{"trials":236,"activeCount":64},[237],{"nctId":149,"briefTitle":150,"status":102,"phases":238,"primaryCompletion":152,"completion":152,"start":153,"enrollment":154,"conditions":239,"interventions":240},[54],[33],[59,84,85,85,98,96,147,157,158,159],{"trials":242,"activeCount":64},[],{"trials":244,"activeCount":64},[],{"intervention":39,"totalTrials":133,"cells":246},{"EARLY_PHASE1":247,"PHASE1":249,"PHASE2":251,"PHASE3":257,"PHASE4":259,"NA":261},{"trials":248,"activeCount":64},[],{"trials":250,"activeCount":64},[],{"trials":252,"activeCount":133,"soonestReadout":38},[253],{"nctId":36,"briefTitle":37,"status":113,"phases":254,"primaryCompletion":38,"completion":115,"start":116,"enrollment":117,"conditions":255,"interventions":256},[53],[109],[39,59,97,85],{"trials":258,"activeCount":64},[],{"trials":260,"activeCount":64},[],{"trials":262,"activeCount":64},[],{"intervention":44,"totalTrials":133,"cells":264},{"EARLY_PHASE1":265,"PHASE1":267,"PHASE2":269,"PHASE3":279,"PHASE4":281,"NA":283},{"trials":266,"activeCount":64},[],{"trials":268,"activeCount":64},[],{"trials":270,"activeCount":133,"soonestReadout":43},[271],{"nctId":41,"briefTitle":42,"status":272,"phases":273,"primaryCompletion":43,"completion":43,"start":274,"enrollment":275,"conditions":276,"interventions":278},"RECRUITING",[53],"2020-06-10",106,[277],"Hepatocellular Carcinoma Non-resectable",[44],{"trials":280,"activeCount":64},[],{"trials":282,"activeCount":64},[],{"trials":284,"activeCount":64},[],{"intervention":49,"totalTrials":133,"cells":286},{"EARLY_PHASE1":287,"PHASE1":289,"PHASE2":291,"PHASE3":293,"PHASE4":295,"NA":297},{"trials":288,"activeCount":64},[],{"trials":290,"activeCount":64},[],{"trials":292,"activeCount":64},[],{"trials":294,"activeCount":64},[],{"trials":296,"activeCount":64},[],{"trials":298,"activeCount":133,"soonestReadout":48},[299],{"nctId":46,"briefTitle":47,"status":113,"phases":300,"primaryCompletion":48,"completion":301,"start":302,"enrollment":303,"conditions":304,"interventions":308},[56],"2030-12","2028-10",140,[305,306,307,24],"Severe Mental Illness","Depression \u002F Major Depressive Disorder","Bipolar Disorder (BD)",[49],{"intervention":96,"totalTrials":310,"cells":311},4,{"EARLY_PHASE1":312,"PHASE1":314,"PHASE2":316,"PHASE3":322,"PHASE4":332,"NA":346},{"trials":313,"activeCount":64},[],{"trials":315,"activeCount":64},[],{"trials":317,"activeCount":64},[318],{"nctId":87,"briefTitle":88,"status":72,"phases":319,"primaryCompletion":90,"completion":91,"start":92,"enrollment":93,"conditions":320,"interventions":321},[53],[33],[96,59,97,83,85,98],{"trials":323,"activeCount":64},[324,328],{"nctId":137,"briefTitle":138,"status":72,"phases":325,"primaryCompletion":140,"completion":141,"start":142,"enrollment":143,"conditions":326,"interventions":327},[54],[145],[147,96,147,59,96],{"nctId":149,"briefTitle":150,"status":102,"phases":329,"primaryCompletion":152,"completion":152,"start":153,"enrollment":154,"conditions":330,"interventions":331},[54],[33],[59,84,85,85,98,96,147,157,158,159],{"trials":333,"activeCount":64},[334],{"nctId":335,"briefTitle":336,"status":102,"phases":337,"primaryCompletion":338,"completion":339,"start":340,"enrollment":341,"conditions":342,"interventions":344},"NCT01767545","Dexamethasone-implant for the Treatment of RVO",[55],"2011-01","2012-02","2010-09",64,[343],"Macular Edema Caused by Retinal Vein Occlusion",[345,96],"Dexamethasone implant",{"trials":347,"activeCount":64},[],{"intervention":349,"totalTrials":350,"cells":351},"Sitagliptin",3,{"EARLY_PHASE1":352,"PHASE1":354,"PHASE2":369,"PHASE3":371,"PHASE4":387,"NA":401},{"trials":353,"activeCount":64},[],{"trials":355,"activeCount":64},[356],{"nctId":357,"briefTitle":358,"status":102,"phases":359,"primaryCompletion":360,"completion":361,"start":362,"enrollment":363,"conditions":364,"interventions":366},"NCT00551590","Effect of Sitagliptin on Incretin Effect in Patients With Type 2 Diabetes Mellitus",[52],"2008-12","2011-09","2007-12",24,[365],"Type 2 Diabetes Mellitus",[349,367,368],"Saline","Exendin(9-39)",{"trials":370,"activeCount":64},[],{"trials":372,"activeCount":64},[373],{"nctId":374,"briefTitle":375,"status":102,"phases":376,"primaryCompletion":377,"completion":378,"start":379,"enrollment":380,"conditions":381,"interventions":383},"NCT00650143","Sitagliptin Plus Granulocyte-colony Stimulating Factor in Acute Myocardial Infarction",[53,54],"2012-06","2013-06","2008-03",174,[382],"Acute Myocardial Infarction",[384,349,385,386],"Lenograstim (GRANOCYTE)=GCSF","Sodium Chloride (NaCl) 0.9 %","Gelatin",{"trials":388,"activeCount":64},[389],{"nctId":390,"briefTitle":391,"status":392,"phases":393,"primaryCompletion":394,"completion":394,"start":395,"enrollment":350,"conditions":396,"interventions":398},"NCT00939939","Effect of Sitagliptin on Postprandial Lipoprotein Metabolism","TERMINATED",[55],"2011-05","2010-03",[397],"Diabetes Mellitus Type 2",[399,400],"sitagliptin","glimepiride",{"trials":402,"activeCount":64},[],{"intervention":404,"totalTrials":133,"cells":405},"Hydrocortisone",{"EARLY_PHASE1":406,"PHASE1":408,"PHASE2":410,"PHASE3":412,"PHASE4":414,"NA":427},{"trials":407,"activeCount":64},[],{"trials":409,"activeCount":64},[],{"trials":411,"activeCount":64},[],{"trials":413,"activeCount":64},[],{"trials":415,"activeCount":64},[416],{"nctId":417,"briefTitle":418,"status":102,"phases":419,"primaryCompletion":420,"completion":421,"start":422,"enrollment":117,"conditions":423,"interventions":426},"NCT00490828","Influence of Hydrocortisone on Immunologic Markers and Health Care Related Quality of Life in Patients After Cardiac Surgery",[55],"2008-05","2008-08","2007-06",[424,425],"Systemic Inflammatory Response Syndrome","Posttraumatic Stress Disorder",[404],{"trials":428,"activeCount":64},[],{"intervention":430,"totalTrials":133,"cells":431},"Niacin\u002F Laropiprant",{"EARLY_PHASE1":432,"PHASE1":434,"PHASE2":436,"PHASE3":438,"PHASE4":440,"NA":453},{"trials":433,"activeCount":64},[],{"trials":435,"activeCount":64},[],{"trials":437,"activeCount":64},[],{"trials":439,"activeCount":64},[],{"trials":441,"activeCount":64},[442],{"nctId":443,"briefTitle":444,"status":392,"phases":445,"primaryCompletion":446,"completion":447,"start":448,"enrollment":16,"conditions":449,"interventions":452},"NCT01239992","Effect of Niacin\u002FLaropiprant on Postprandial Lipoprotein Metabolism in Patients With Dyslipoproteinemia",[55],"2013-01","2013-07","2011-06",[450,451],"Hyperlipoproteinemia","Metabolic Syndrome",[430],{"trials":454,"activeCount":64},[],{"intervention":400,"totalTrials":133,"cells":456},{"EARLY_PHASE1":457,"PHASE1":459,"PHASE2":461,"PHASE3":463,"PHASE4":465,"NA":471},{"trials":458,"activeCount":64},[],{"trials":460,"activeCount":64},[],{"trials":462,"activeCount":64},[],{"trials":464,"activeCount":64},[],{"trials":466,"activeCount":64},[467],{"nctId":390,"briefTitle":391,"status":392,"phases":468,"primaryCompletion":394,"completion":394,"start":395,"enrollment":350,"conditions":469,"interventions":470},[55],[397],[399,400],{"trials":472,"activeCount":64},[],{"intervention":345,"totalTrials":133,"cells":474},{"EARLY_PHASE1":475,"PHASE1":477,"PHASE2":479,"PHASE3":481,"PHASE4":483,"NA":489},{"trials":476,"activeCount":64},[],{"trials":478,"activeCount":64},[],{"trials":480,"activeCount":64},[],{"trials":482,"activeCount":64},[],{"trials":484,"activeCount":64},[485],{"nctId":335,"briefTitle":336,"status":102,"phases":486,"primaryCompletion":338,"completion":339,"start":340,"enrollment":341,"conditions":487,"interventions":488},[55],[343],[345,96],{"trials":490,"activeCount":64},[],{"intervention":492,"totalTrials":133,"cells":493},"pegvisomant",{"EARLY_PHASE1":494,"PHASE1":496,"PHASE2":498,"PHASE3":500,"PHASE4":502,"NA":514},{"trials":495,"activeCount":64},[],{"trials":497,"activeCount":64},[],{"trials":499,"activeCount":64},[],{"trials":501,"activeCount":64},[],{"trials":503,"activeCount":64},[504],{"nctId":505,"briefTitle":506,"status":102,"phases":507,"primaryCompletion":379,"completion":379,"start":508,"enrollment":19,"conditions":509,"interventions":511},"NCT00595140","Acute Application of Pegvisomant and Octreotide in Acromegaly",[55],"2008-01",[510],"Acromegaly",[492,512,513],"combination with somatostatin analogue octreotide","combination with dopamine agonist cabergoline",{"trials":515,"activeCount":64},[],{"intervention":512,"totalTrials":133,"cells":517},{"EARLY_PHASE1":518,"PHASE1":520,"PHASE2":522,"PHASE3":524,"PHASE4":526,"NA":532},{"trials":519,"activeCount":64},[],{"trials":521,"activeCount":64},[],{"trials":523,"activeCount":64},[],{"trials":525,"activeCount":64},[],{"trials":527,"activeCount":64},[528],{"nctId":505,"briefTitle":506,"status":102,"phases":529,"primaryCompletion":379,"completion":379,"start":508,"enrollment":19,"conditions":530,"interventions":531},[55],[510],[492,512,513],{"trials":533,"activeCount":64},[],{"intervention":513,"totalTrials":133,"cells":535},{"EARLY_PHASE1":536,"PHASE1":538,"PHASE2":540,"PHASE3":542,"PHASE4":544,"NA":550},{"trials":537,"activeCount":64},[],{"trials":539,"activeCount":64},[],{"trials":541,"activeCount":64},[],{"trials":543,"activeCount":64},[],{"trials":545,"activeCount":64},[546],{"nctId":505,"briefTitle":506,"status":102,"phases":547,"primaryCompletion":379,"completion":379,"start":508,"enrollment":19,"conditions":548,"interventions":549},[55],[510],[492,512,513],{"trials":551,"activeCount":64},[],{"intervention":553,"totalTrials":133,"cells":554},"Prasugrel or Ticagrelor",{"EARLY_PHASE1":555,"PHASE1":557,"PHASE2":559,"PHASE3":561,"PHASE4":563,"NA":578},{"trials":556,"activeCount":64},[],{"trials":558,"activeCount":64},[],{"trials":560,"activeCount":64},[],{"trials":562,"activeCount":64},[],{"trials":564,"activeCount":64},[565],{"nctId":566,"briefTitle":567,"status":102,"phases":568,"primaryCompletion":569,"completion":570,"start":571,"enrollment":572,"conditions":573,"interventions":576},"NCT04981041","Escalated Single Platelet Inhibition for One Month Plus NOAC in Patients With Atrial Fibrillation and ACS Undergoing PCI",[55],"2026-05-22","2026-05-30","2021-12-16",602,[574,575],"Acute Coronary Syndrome","Atrial Fibrillation",[553,577],"Clopidogrel",{"trials":579,"activeCount":64},[],{"intervention":577,"totalTrials":133,"cells":581},{"EARLY_PHASE1":582,"PHASE1":584,"PHASE2":586,"PHASE3":588,"PHASE4":590,"NA":596},{"trials":583,"activeCount":64},[],{"trials":585,"activeCount":64},[],{"trials":587,"activeCount":64},[],{"trials":589,"activeCount":64},[],{"trials":591,"activeCount":64},[592],{"nctId":566,"briefTitle":567,"status":102,"phases":593,"primaryCompletion":569,"completion":570,"start":571,"enrollment":572,"conditions":594,"interventions":595},[55],[574,575],[553,577],{"trials":597,"activeCount":64},[],{"intervention":599,"totalTrials":133,"cells":600},"Risperidone, Haloperidol",{"EARLY_PHASE1":601,"PHASE1":603,"PHASE2":605,"PHASE3":607,"PHASE4":609,"NA":621},{"trials":602,"activeCount":64},[],{"trials":604,"activeCount":64},[],{"trials":606,"activeCount":64},[],{"trials":608,"activeCount":64},[],{"trials":610,"activeCount":64},[611],{"nctId":612,"briefTitle":613,"status":72,"phases":614,"completion":615,"start":616,"enrollment":617,"conditions":618,"interventions":620},"NCT00157378","Optimization of Acute Treatment in First Episode Schizophrenia",[55],"2004-12","2000-11",300,[619],"Schizophrenia, First-Episode",[599],{"trials":622,"activeCount":64},[],{"intervention":624,"totalTrials":133,"cells":625},"Sertralin",{"EARLY_PHASE1":626,"PHASE1":628,"PHASE2":630,"PHASE3":632,"PHASE4":634,"NA":643},{"trials":627,"activeCount":64},[],{"trials":629,"activeCount":64},[],{"trials":631,"activeCount":64},[],{"trials":633,"activeCount":64},[],{"trials":635,"activeCount":64},[636],{"nctId":637,"briefTitle":638,"status":72,"phases":639,"enrollment":640,"conditions":641,"interventions":642},"NCT00226642","Treatment of Mild and Subthreshold Depressive Disorders",[55],369,[15],[624],{"trials":644,"activeCount":64},[],{"intervention":646,"totalTrials":133,"cells":647},"Galantamine",{"EARLY_PHASE1":648,"PHASE1":650,"PHASE2":652,"PHASE3":654,"PHASE4":656,"NA":668},{"trials":649,"activeCount":64},[],{"trials":651,"activeCount":64},[],{"trials":653,"activeCount":64},[],{"trials":655,"activeCount":64},[],{"trials":657,"activeCount":64},[658],{"nctId":659,"briefTitle":660,"status":72,"phases":661,"completion":662,"start":663,"enrollment":664,"conditions":665,"interventions":667},"NCT00523666","Diffusion Tensor Weighted MRI in Alzheimer's Disease Modifying Treatment Effects of Galantamine (Reminyl®)",[55],"2008-09","2006-09",20,[666],"Alzheimer's Disease",[646],{"trials":669,"activeCount":64},[],{"intervention":671,"totalTrials":133,"cells":672},"0.5% levofloxacin eye drops",{"EARLY_PHASE1":673,"PHASE1":675,"PHASE2":677,"PHASE3":679,"PHASE4":681,"NA":691},{"trials":674,"activeCount":64},[],{"trials":676,"activeCount":64},[],{"trials":678,"activeCount":64},[],{"trials":680,"activeCount":64},[],{"trials":682,"activeCount":64},[683],{"nctId":684,"briefTitle":685,"status":102,"phases":686,"completion":687,"start":125,"enrollment":303,"conditions":688,"interventions":690},"NCT00491049","Effectiveness of Topical 0.5% Levofloxacin to Reduce the Conjunctival Bacterial Flora Before Intraocular Surgery",[55],"2005-04",[689],"Conjunctival Bacterial Flora",[671],{"trials":692,"activeCount":64},[],{"intervention":147,"totalTrials":310,"cells":694},{"EARLY_PHASE1":695,"PHASE1":697,"PHASE2":699,"PHASE3":717,"PHASE4":727,"NA":729},{"trials":696,"activeCount":64},[],{"trials":698,"activeCount":64},[],{"trials":700,"activeCount":64},[701,713],{"nctId":702,"briefTitle":703,"status":102,"phases":704,"start":705,"enrollment":706,"conditions":707,"interventions":709},"NCT00480597","Gemcitabine\u002FVinorelbine Versus Gemcitabine\u002FCisplatin Versus Gemcitabine\u002FCapecitabine in Metastatic Breast Cancer",[53],"2002-10",141,[708],"Metastatic Breast Cancer",[710,711,712,129],"gemcitabine","cisplatin","vinorelbine",{"nctId":121,"briefTitle":122,"status":102,"phases":714,"completion":124,"start":125,"enrollment":126,"conditions":715,"interventions":716},[53],[33],[129,130,131,132],{"trials":718,"activeCount":64},[719,723],{"nctId":137,"briefTitle":138,"status":72,"phases":720,"primaryCompletion":140,"completion":141,"start":142,"enrollment":143,"conditions":721,"interventions":722},[54],[145],[147,96,147,59,96],{"nctId":149,"briefTitle":150,"status":102,"phases":724,"primaryCompletion":152,"completion":152,"start":153,"enrollment":154,"conditions":725,"interventions":726},[54],[33],[59,84,85,85,98,96,147,157,158,159],{"trials":728,"activeCount":64},[],{"trials":730,"activeCount":64},[],{"intervention":98,"totalTrials":310,"cells":732},{"EARLY_PHASE1":733,"PHASE1":735,"PHASE2":737,"PHASE3":751,"PHASE4":757,"NA":759},{"trials":734,"activeCount":64},[],{"trials":736,"activeCount":64},[],{"trials":738,"activeCount":64},[739,743,747],{"nctId":87,"briefTitle":88,"status":72,"phases":740,"primaryCompletion":90,"completion":91,"start":92,"enrollment":93,"conditions":741,"interventions":742},[53],[33],[96,59,97,83,85,98],{"nctId":100,"briefTitle":101,"status":102,"phases":744,"primaryCompletion":104,"completion":105,"start":106,"enrollment":107,"conditions":745,"interventions":746},[53],[109],[85,84,59,98,111],{"nctId":121,"briefTitle":122,"status":102,"phases":748,"completion":124,"start":125,"enrollment":126,"conditions":749,"interventions":750},[53],[33],[129,130,131,132],{"trials":752,"activeCount":64},[753],{"nctId":149,"briefTitle":150,"status":102,"phases":754,"primaryCompletion":152,"completion":152,"start":153,"enrollment":154,"conditions":755,"interventions":756},[54],[33],[59,84,85,85,98,96,147,157,158,159],{"trials":758,"activeCount":64},[],{"trials":760,"activeCount":64},[],{"intervention":762,"totalTrials":763,"cells":764},"carboplatin",2,{"EARLY_PHASE1":765,"PHASE1":767,"PHASE2":769,"PHASE3":780,"PHASE4":794,"NA":796},{"trials":766,"activeCount":64},[],{"trials":768,"activeCount":64},[],{"trials":770,"activeCount":64},[771],{"nctId":772,"briefTitle":773,"status":102,"phases":774,"completion":775,"start":776,"conditions":777,"interventions":779},"NCT00450762","Gemcitabine + Carboplatin in Breast Cancer",[53],"2006-10","2004-03",[778],"Breast Cancer",[710,762],{"trials":781,"activeCount":64},[782],{"nctId":783,"briefTitle":784,"status":72,"phases":785,"start":786,"enrollment":787,"conditions":788,"interventions":792},"NCT00045461","Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer",[53,54],"2000-06",241,[789,790,791],"Fallopian Tube Cancer","Ovarian Cancer","Primary Peritoneal Cavity Cancer",[762,793],"ifosfamide",{"trials":795,"activeCount":64},[],{"trials":797,"activeCount":64},[],{"intervention":799,"totalTrials":133,"cells":800},"FEC-DocGemzar adjuvant chemotherapy",{"EARLY_PHASE1":801,"PHASE1":803,"PHASE2":805,"PHASE3":807,"PHASE4":822,"NA":824},{"trials":802,"activeCount":64},[],{"trials":804,"activeCount":64},[],{"trials":806,"activeCount":64},[],{"trials":808,"activeCount":64},[809],{"nctId":810,"briefTitle":811,"status":102,"phases":812,"primaryCompletion":813,"completion":813,"start":814,"enrollment":815,"conditions":816,"interventions":818},"NCT02181101","Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-Trial",[54],"2013-09","2005-09",3754,[817],"Breast Neoplasms",[799,819,820,821],"FEC-Doc adjuvant chemotherapy","Zoledronic acid i.v. 2 years","Zoledronic acid i.v. 5 years",{"trials":823,"activeCount":64},[],{"trials":825,"activeCount":64},[],{"intervention":819,"totalTrials":133,"cells":827},{"EARLY_PHASE1":828,"PHASE1":830,"PHASE2":832,"PHASE3":834,"PHASE4":840,"NA":842},{"trials":829,"activeCount":64},[],{"trials":831,"activeCount":64},[],{"trials":833,"activeCount":64},[],{"trials":835,"activeCount":64},[836],{"nctId":810,"briefTitle":811,"status":102,"phases":837,"primaryCompletion":813,"completion":813,"start":814,"enrollment":815,"conditions":838,"interventions":839},[54],[817],[799,819,820,821],{"trials":841,"activeCount":64},[],{"trials":843,"activeCount":64},[],{"intervention":820,"totalTrials":133,"cells":845},{"EARLY_PHASE1":846,"PHASE1":848,"PHASE2":850,"PHASE3":852,"PHASE4":858,"NA":860},{"trials":847,"activeCount":64},[],{"trials":849,"activeCount":64},[],{"trials":851,"activeCount":64},[],{"trials":853,"activeCount":64},[854],{"nctId":810,"briefTitle":811,"status":102,"phases":855,"primaryCompletion":813,"completion":813,"start":814,"enrollment":815,"conditions":856,"interventions":857},[54],[817],[799,819,820,821],{"trials":859,"activeCount":64},[],{"trials":861,"activeCount":64},[],{"intervention":821,"totalTrials":133,"cells":863},{"EARLY_PHASE1":864,"PHASE1":866,"PHASE2":868,"PHASE3":870,"PHASE4":876,"NA":878},{"trials":865,"activeCount":64},[],{"trials":867,"activeCount":64},[],{"trials":869,"activeCount":64},[],{"trials":871,"activeCount":64},[872],{"nctId":810,"briefTitle":811,"status":102,"phases":873,"primaryCompletion":813,"completion":813,"start":814,"enrollment":815,"conditions":874,"interventions":875},[54],[817],[799,819,820,821],{"trials":877,"activeCount":64},[],{"trials":879,"activeCount":64},[],{"intervention":881,"totalTrials":133,"cells":882},"Treatment with levetiracetam or sulthiame over a six-month period.",{"EARLY_PHASE1":883,"PHASE1":885,"PHASE2":887,"PHASE3":889,"PHASE4":901,"NA":903},{"trials":884,"activeCount":64},[],{"trials":886,"activeCount":64},[],{"trials":888,"activeCount":64},[],{"trials":890,"activeCount":64},[891],{"nctId":892,"briefTitle":893,"status":392,"phases":894,"completion":895,"start":896,"enrollment":897,"conditions":898,"interventions":900},"NCT00471744","HEAD-Study Optimizing the Treatment of Children With BECTS",[54],"2008-07","2006-06",44,[899],"Epilepsy, Rolandic",[881],{"trials":902,"activeCount":64},[],{"trials":904,"activeCount":64},[],{"intervention":906,"totalTrials":133,"cells":907},"rituximab maintenance",{"EARLY_PHASE1":908,"PHASE1":910,"PHASE2":912,"PHASE3":914,"PHASE4":929,"NA":931},{"trials":909,"activeCount":64},[],{"trials":911,"activeCount":64},[],{"trials":913,"activeCount":64},[],{"trials":915,"activeCount":64},[916],{"nctId":917,"briefTitle":918,"status":72,"phases":919,"primaryCompletion":920,"completion":921,"start":922,"enrollment":923,"conditions":924,"interventions":928},"NCT00317096","FCM Versus R-FCM Followed by R-Maintenance or Observation Only",[54],"2001-06","2021-06","1998-11",319,[925,926,927],"Lymphoma, Follicular","Lymphoma, Low-Grade","Lymphoma, Intermediate-Grade",[906],{"trials":930,"activeCount":64},[],{"trials":932,"activeCount":64},[],{"intervention":793,"totalTrials":133,"cells":934},{"EARLY_PHASE1":935,"PHASE1":937,"PHASE2":939,"PHASE3":941,"PHASE4":947,"NA":949},{"trials":936,"activeCount":64},[],{"trials":938,"activeCount":64},[],{"trials":940,"activeCount":64},[],{"trials":942,"activeCount":64},[943],{"nctId":783,"briefTitle":784,"status":72,"phases":944,"start":786,"enrollment":787,"conditions":945,"interventions":946},[53,54],[789,790,791],[762,793],{"trials":948,"activeCount":64},[],{"trials":950,"activeCount":64},[],{"intervention":952,"totalTrials":133,"cells":953},"Genotropin",{"EARLY_PHASE1":954,"PHASE1":956,"PHASE2":958,"PHASE3":960,"PHASE4":973,"NA":975},{"trials":955,"activeCount":64},[],{"trials":957,"activeCount":64},[],{"trials":959,"activeCount":64},[],{"trials":961,"activeCount":64},[962],{"nctId":963,"briefTitle":964,"status":102,"phases":965,"completion":966,"start":967,"enrollment":968,"conditions":969,"interventions":972},"NCT00420251","Efficacy and Safety of Growth Hormone Treatment in Juvenile Idiopathic Arthritis",[54],"2006-07","1996-03",50,[970,971],"Juvenile Idiopathic Arthritis","Still Disease, Juvenile-Onset",[952],{"trials":974,"activeCount":64},[],{"trials":976,"activeCount":64},[],{"intervention":978,"totalTrials":133,"cells":979},"mipomersen",{"EARLY_PHASE1":980,"PHASE1":982,"PHASE2":984,"PHASE3":986,"PHASE4":1000,"NA":1002},{"trials":981,"activeCount":64},[],{"trials":983,"activeCount":64},[],{"trials":985,"activeCount":64},[],{"trials":987,"activeCount":64},[988],{"nctId":989,"briefTitle":990,"status":102,"phases":991,"primaryCompletion":992,"completion":993,"start":994,"enrollment":995,"conditions":996,"interventions":999},"NCT01598948","Effect of Mipomersen on LDL-Cholesterol Levels in Patients Treated by Regular Apheresis",[54],"2015-05","2015-06","2012-08",17,[997,998],"Atherosclerosis","LDL-hypercholesterolemia",[978],{"trials":1001,"activeCount":64},[],{"trials":1003,"activeCount":64},[],{"intervention":1005,"totalTrials":133,"cells":1006},"Etoricoxibe",{"EARLY_PHASE1":1007,"PHASE1":1009,"PHASE2":1011,"PHASE3":1013,"PHASE4":1027,"NA":1029},{"trials":1008,"activeCount":64},[],{"trials":1010,"activeCount":64},[],{"trials":1012,"activeCount":64},[],{"trials":1014,"activeCount":64},[1015],{"nctId":1016,"briefTitle":1017,"status":392,"phases":1018,"primaryCompletion":142,"completion":1019,"start":1020,"enrollment":1021,"conditions":1022,"interventions":1026},"NCT00716833","Etoricoxibe - Preemptive and Postoperative Analgesia for Abdominal and Thoracic Surgery",[54],"2011-12","2006-02",87,[1023,1024,1025],"Pain","Abdominal Surgery","Thoracic Surgery",[1005],{"trials":1028,"activeCount":64},[],{"trials":1030,"activeCount":64},[],{"intervention":1032,"totalTrials":133,"cells":1033},"deflazacort",{"EARLY_PHASE1":1034,"PHASE1":1036,"PHASE2":1038,"PHASE3":1040,"PHASE4":1054,"NA":1056},{"trials":1035,"activeCount":64},[],{"trials":1037,"activeCount":64},[],{"trials":1039,"activeCount":64},[],{"trials":1041,"activeCount":64},[1042],{"nctId":1043,"briefTitle":1044,"status":102,"phases":1045,"primaryCompletion":1046,"completion":662,"start":1047,"enrollment":1048,"conditions":1049,"interventions":1053},"NCT00527228","Deflazacort in Dysferlinopathies",[53,54],"2008-04","2003-09",25,[1050,1051,1052],"LGMD2B","Miyoshi Myopathy","Dysferlinopathy",[1032],{"trials":1055,"activeCount":64},[],{"trials":1057,"activeCount":64},[],{"intervention":1059,"totalTrials":133,"cells":1060},"quetiapine",{"EARLY_PHASE1":1061,"PHASE1":1063,"PHASE2":1065,"PHASE3":1067,"PHASE4":1079,"NA":1081},{"trials":1062,"activeCount":64},[],{"trials":1064,"activeCount":64},[],{"trials":1066,"activeCount":64},[],{"trials":1068,"activeCount":64},[1069],{"nctId":1070,"briefTitle":1071,"status":102,"phases":1072,"primaryCompletion":339,"completion":339,"start":1073,"enrollment":1074,"conditions":1075,"interventions":1077},"NCT00953108","Quetiapine Prolong, Escitalopram and Hypothalamic-pituitary-adrenocortical (HPA) Axis Activity in Depressed Patients",[54],"2009-09",60,[1076],"Major Depression",[1059,1078],"escitalopram",{"trials":1080,"activeCount":64},[],{"trials":1082,"activeCount":64},[],{"intervention":1078,"totalTrials":133,"cells":1084},{"EARLY_PHASE1":1085,"PHASE1":1087,"PHASE2":1089,"PHASE3":1091,"PHASE4":1097,"NA":1099},{"trials":1086,"activeCount":64},[],{"trials":1088,"activeCount":64},[],{"trials":1090,"activeCount":64},[],{"trials":1092,"activeCount":64},[1093],{"nctId":1070,"briefTitle":1071,"status":102,"phases":1094,"primaryCompletion":339,"completion":339,"start":1073,"enrollment":1074,"conditions":1095,"interventions":1096},[54],[1076],[1059,1078],{"trials":1098,"activeCount":64},[],{"trials":1100,"activeCount":64},[],{"intervention":157,"totalTrials":133,"cells":1102},{"EARLY_PHASE1":1103,"PHASE1":1105,"PHASE2":1107,"PHASE3":1109,"PHASE4":1115,"NA":1117},{"trials":1104,"activeCount":64},[],{"trials":1106,"activeCount":64},[],{"trials":1108,"activeCount":64},[],{"trials":1110,"activeCount":64},[1111],{"nctId":149,"briefTitle":150,"status":102,"phases":1112,"primaryCompletion":152,"completion":152,"start":153,"enrollment":154,"conditions":1113,"interventions":1114},[54],[33],[59,84,85,85,98,96,147,157,158,159],{"trials":1116,"activeCount":64},[],{"trials":1118,"activeCount":64},[],{"intervention":158,"totalTrials":133,"cells":1120},{"EARLY_PHASE1":1121,"PHASE1":1123,"PHASE2":1125,"PHASE3":1127,"PHASE4":1133,"NA":1135},{"trials":1122,"activeCount":64},[],{"trials":1124,"activeCount":64},[],{"trials":1126,"activeCount":64},[],{"trials":1128,"activeCount":64},[1129],{"nctId":149,"briefTitle":150,"status":102,"phases":1130,"primaryCompletion":152,"completion":152,"start":153,"enrollment":154,"conditions":1131,"interventions":1132},[54],[33],[59,84,85,85,98,96,147,157,158,159],{"trials":1134,"activeCount":64},[],{"trials":1136,"activeCount":64},[],{"intervention":159,"totalTrials":133,"cells":1138},{"EARLY_PHASE1":1139,"PHASE1":1141,"PHASE2":1143,"PHASE3":1145,"PHASE4":1151,"NA":1153},{"trials":1140,"activeCount":64},[],{"trials":1142,"activeCount":64},[],{"trials":1144,"activeCount":64},[],{"trials":1146,"activeCount":64},[1147],{"nctId":149,"briefTitle":150,"status":102,"phases":1148,"primaryCompletion":152,"completion":152,"start":153,"enrollment":154,"conditions":1149,"interventions":1150},[54],[33],[59,84,85,85,98,96,147,157,158,159],{"trials":1152,"activeCount":64},[],{"trials":1154,"activeCount":64},[],{"intervention":384,"totalTrials":133,"cells":1156},{"EARLY_PHASE1":1157,"PHASE1":1159,"PHASE2":1161,"PHASE3":1163,"PHASE4":1169,"NA":1171},{"trials":1158,"activeCount":64},[],{"trials":1160,"activeCount":64},[],{"trials":1162,"activeCount":64},[],{"trials":1164,"activeCount":64},[1165],{"nctId":374,"briefTitle":375,"status":102,"phases":1166,"primaryCompletion":377,"completion":378,"start":379,"enrollment":380,"conditions":1167,"interventions":1168},[53,54],[382],[384,349,385,386],{"trials":1170,"activeCount":64},[],{"trials":1172,"activeCount":64},[],{"intervention":385,"totalTrials":133,"cells":1174},{"EARLY_PHASE1":1175,"PHASE1":1177,"PHASE2":1179,"PHASE3":1181,"PHASE4":1187,"NA":1189},{"trials":1176,"activeCount":64},[],{"trials":1178,"activeCount":64},[],{"trials":1180,"activeCount":64},[],{"trials":1182,"activeCount":64},[1183],{"nctId":374,"briefTitle":375,"status":102,"phases":1184,"primaryCompletion":377,"completion":378,"start":379,"enrollment":380,"conditions":1185,"interventions":1186},[53,54],[382],[384,349,385,386],{"trials":1188,"activeCount":64},[],{"trials":1190,"activeCount":64},[],{"intervention":386,"totalTrials":133,"cells":1192},{"EARLY_PHASE1":1193,"PHASE1":1195,"PHASE2":1197,"PHASE3":1199,"PHASE4":1205,"NA":1207},{"trials":1194,"activeCount":64},[],{"trials":1196,"activeCount":64},[],{"trials":1198,"activeCount":64},[],{"trials":1200,"activeCount":64},[1201],{"nctId":374,"briefTitle":375,"status":102,"phases":1202,"primaryCompletion":377,"completion":378,"start":379,"enrollment":380,"conditions":1203,"interventions":1204},[53,54],[382],[384,349,385,386],{"trials":1206,"activeCount":64},[],{"trials":1208,"activeCount":64},[],{"intervention":1210,"totalTrials":133,"cells":1211},"1,2 dithiolane 3 valeric acid",{"EARLY_PHASE1":1212,"PHASE1":1214,"PHASE2":1216,"PHASE3":1218,"PHASE4":1231,"NA":1233},{"trials":1213,"activeCount":64},[],{"trials":1215,"activeCount":64},[],{"trials":1217,"activeCount":64},[],{"trials":1219,"activeCount":64},[1220],{"nctId":1221,"briefTitle":1222,"status":102,"phases":1223,"primaryCompletion":687,"completion":1224,"start":1225,"enrollment":1226,"conditions":1227,"interventions":1230},"NCT01208948","Clinical Trial on Alpha Lipoic Acid in Diabetic Macular Edema",[54],"2005-12","2000-07",520,[1228,1229],"Diabetes Mellitus","Macular Edema",[1210],{"trials":1232,"activeCount":64},[],{"trials":1234,"activeCount":64},[],{"intervention":1236,"totalTrials":133,"cells":1237},"Amlodipine",{"EARLY_PHASE1":1238,"PHASE1":1240,"PHASE2":1242,"PHASE3":1244,"PHASE4":1258,"NA":1260},{"trials":1239,"activeCount":64},[],{"trials":1241,"activeCount":64},[],{"trials":1243,"activeCount":64},[],{"trials":1245,"activeCount":64},[1246],{"nctId":1247,"briefTitle":1248,"status":392,"phases":1249,"primaryCompletion":1250,"completion":1250,"start":1251,"enrollment":1252,"conditions":1253,"interventions":1255},"NCT03082014","Effects of Amlodipine and Other Blood Pressure Lowering Agents on Microvascular Function",[54],"2022-07-28","2018-02-22",101,[1254],"Cerebral Small Vessel Diseases",[1236,1256,1257],"Losartan","Atenolol",{"trials":1259,"activeCount":64},[],{"trials":1261,"activeCount":64},[],{"intervention":1256,"totalTrials":133,"cells":1263},{"EARLY_PHASE1":1264,"PHASE1":1266,"PHASE2":1268,"PHASE3":1270,"PHASE4":1276,"NA":1278},{"trials":1265,"activeCount":64},[],{"trials":1267,"activeCount":64},[],{"trials":1269,"activeCount":64},[],{"trials":1271,"activeCount":64},[1272],{"nctId":1247,"briefTitle":1248,"status":392,"phases":1273,"primaryCompletion":1250,"completion":1250,"start":1251,"enrollment":1252,"conditions":1274,"interventions":1275},[54],[1254],[1236,1256,1257],{"trials":1277,"activeCount":64},[],{"trials":1279,"activeCount":64},[],{"intervention":1257,"totalTrials":133,"cells":1281},{"EARLY_PHASE1":1282,"PHASE1":1284,"PHASE2":1286,"PHASE3":1288,"PHASE4":1294,"NA":1296},{"trials":1283,"activeCount":64},[],{"trials":1285,"activeCount":64},[],{"trials":1287,"activeCount":64},[],{"trials":1289,"activeCount":64},[1290],{"nctId":1247,"briefTitle":1248,"status":392,"phases":1291,"primaryCompletion":1250,"completion":1250,"start":1251,"enrollment":1252,"conditions":1292,"interventions":1293},[54],[1254],[1236,1256,1257],{"trials":1295,"activeCount":64},[],{"trials":1297,"activeCount":64},[],{"intervention":1299,"totalTrials":133,"cells":1300},"Tacrolimus",{"EARLY_PHASE1":1301,"PHASE1":1303,"PHASE2":1305,"PHASE3":1307,"PHASE4":1322,"NA":1324},{"trials":1302,"activeCount":64},[],{"trials":1304,"activeCount":64},[],{"trials":1306,"activeCount":64},[],{"trials":1308,"activeCount":64},[1309],{"nctId":1310,"briefTitle":1311,"status":392,"phases":1312,"primaryCompletion":447,"completion":447,"start":1313,"enrollment":1048,"conditions":1314,"interventions":1320},"NCT01564095","TOP-Study (Tacrolimus Organ Perfusion): Treatment of Ischemia Reperfusion Injury in Marginal Organs With an ex Vivo Tacrolimus Perfusion",[53,54],"2011-10",[1315,1316,1317,1318,1319],"Terminal Liver Disease","Ischemia Reperfusion Injury","Graft Dysfunction","Graft Failure","Poor Graft Quality",[1299,1321],"HTK\u002FPlacebo",{"trials":1323,"activeCount":64},[],{"trials":1325,"activeCount":64},[],{"intervention":1321,"totalTrials":133,"cells":1327},{"EARLY_PHASE1":1328,"PHASE1":1330,"PHASE2":1332,"PHASE3":1334,"PHASE4":1340,"NA":1342},{"trials":1329,"activeCount":64},[],{"trials":1331,"activeCount":64},[],{"trials":1333,"activeCount":64},[],{"trials":1335,"activeCount":64},[1336],{"nctId":1310,"briefTitle":1311,"status":392,"phases":1337,"primaryCompletion":447,"completion":447,"start":1313,"enrollment":1048,"conditions":1338,"interventions":1339},[53,54],[1315,1316,1317,1318,1319],[1299,1321],{"trials":1341,"activeCount":64},[],{"trials":1343,"activeCount":64},[],{"intervention":1345,"totalTrials":133,"cells":1346},"telmisartan",{"EARLY_PHASE1":1347,"PHASE1":1349,"PHASE2":1351,"PHASE3":1353,"PHASE4":1366,"NA":1368},{"trials":1348,"activeCount":64},[],{"trials":1350,"activeCount":64},[],{"trials":1352,"activeCount":64},[],{"trials":1354,"activeCount":64},[1355],{"nctId":1356,"briefTitle":1357,"status":102,"phases":1358,"primaryCompletion":1073,"completion":1359,"start":1360,"enrollment":1361,"conditions":1362,"interventions":1365},"NCT00560430","Regulation of Inflammatory Parameters by Telmisartan in Hypertensive Patients",[54],"2009-10","2007-11",56,[1363,451,1364],"Hypertension","Hypertriglyceridemia",[1345,1345],{"trials":1367,"activeCount":64},[],{"trials":1369,"activeCount":64},[],{"intervention":1371,"totalTrials":133,"cells":1372},"Iloprost",{"EARLY_PHASE1":1373,"PHASE1":1375,"PHASE2":1377,"PHASE3":1379,"PHASE4":1392,"NA":1394},{"trials":1374,"activeCount":64},[],{"trials":1376,"activeCount":64},[],{"trials":1378,"activeCount":64},[],{"trials":1380,"activeCount":64},[1381],{"nctId":1382,"briefTitle":1383,"status":102,"phases":1384,"primaryCompletion":1385,"completion":1385,"start":1386,"enrollment":1387,"conditions":1388,"interventions":1390},"NCT00927654","Iloprost in High Risk Cardiac Surgical Patients",[54],"2012-03","2009-06",253,[1389],"Pulmonary Hypertension",[1371,1391],"Isotonic Sodium Chloride solution 0.9 %",{"trials":1393,"activeCount":64},[],{"trials":1395,"activeCount":64},[],{"intervention":1391,"totalTrials":133,"cells":1397},{"EARLY_PHASE1":1398,"PHASE1":1400,"PHASE2":1402,"PHASE3":1404,"PHASE4":1410,"NA":1412},{"trials":1399,"activeCount":64},[],{"trials":1401,"activeCount":64},[],{"trials":1403,"activeCount":64},[],{"trials":1405,"activeCount":64},[1406],{"nctId":1382,"briefTitle":1383,"status":102,"phases":1407,"primaryCompletion":1385,"completion":1385,"start":1386,"enrollment":1387,"conditions":1408,"interventions":1409},[54],[1389],[1371,1391],{"trials":1411,"activeCount":64},[],{"trials":1413,"activeCount":64},[],{"intervention":1415,"totalTrials":133,"cells":1416},"3 x FEC 3 x DOC \u002F Gemcitabine",{"EARLY_PHASE1":1417,"PHASE1":1419,"PHASE2":1421,"PHASE3":1423,"PHASE4":1434,"NA":1436},{"trials":1418,"activeCount":64},[],{"trials":1420,"activeCount":64},[],{"trials":1422,"activeCount":64},[],{"trials":1424,"activeCount":64},[1425],{"nctId":1426,"briefTitle":1427,"status":102,"phases":1428,"primaryCompletion":1313,"start":1429,"enrollment":1430,"conditions":1431,"interventions":1432},"NCT00670878","Studying the Benefits of Adjuvant Sequential vs. Combined Taxane Based Chemotherapy, Followed by Different Biological Treatment Strategies in Early, HER2-positive Breast Cancer",[54],"2008-06",799,[778],[1415,1433],"3 x FEC 3 x DOC",{"trials":1435,"activeCount":64},[],{"trials":1437,"activeCount":64},[],{"intervention":1433,"totalTrials":133,"cells":1439},{"EARLY_PHASE1":1440,"PHASE1":1442,"PHASE2":1444,"PHASE3":1446,"PHASE4":1452,"NA":1454},{"trials":1441,"activeCount":64},[],{"trials":1443,"activeCount":64},[],{"trials":1445,"activeCount":64},[],{"trials":1447,"activeCount":64},[1448],{"nctId":1426,"briefTitle":1427,"status":102,"phases":1449,"primaryCompletion":1313,"start":1429,"enrollment":1430,"conditions":1450,"interventions":1451},[54],[778],[1415,1433],{"trials":1453,"activeCount":64},[],{"trials":1455,"activeCount":64},[],{"intervention":1457,"totalTrials":133,"cells":1458},"cyclophosphamide",{"EARLY_PHASE1":1459,"PHASE1":1461,"PHASE2":1463,"PHASE3":1465,"PHASE4":1480,"NA":1482},{"trials":1460,"activeCount":64},[],{"trials":1462,"activeCount":64},[],{"trials":1464,"activeCount":64},[],{"trials":1466,"activeCount":64},[1467],{"nctId":1468,"briefTitle":1469,"status":102,"phases":1470,"primaryCompletion":339,"completion":1385,"start":1471,"enrollment":1472,"conditions":1473,"interventions":1474},"NCT00047099","Combination Chemotherapy in Treating Women With Breast Cancer",[54],"2001-08",446,[778],[1457,1475,1476,1477,1478,1479],"docetaxel","epirubicin hydrochloride","fluorouracil","goserelin acetate","tamoxifen citrate",{"trials":1481,"activeCount":64},[],{"trials":1483,"activeCount":64},[],{"intervention":1475,"totalTrials":133,"cells":1485},{"EARLY_PHASE1":1486,"PHASE1":1488,"PHASE2":1490,"PHASE3":1492,"PHASE4":1498,"NA":1500},{"trials":1487,"activeCount":64},[],{"trials":1489,"activeCount":64},[],{"trials":1491,"activeCount":64},[],{"trials":1493,"activeCount":64},[1494],{"nctId":1468,"briefTitle":1469,"status":102,"phases":1495,"primaryCompletion":339,"completion":1385,"start":1471,"enrollment":1472,"conditions":1496,"interventions":1497},[54],[778],[1457,1475,1476,1477,1478,1479],{"trials":1499,"activeCount":64},[],{"trials":1501,"activeCount":64},[],{"intervention":1476,"totalTrials":133,"cells":1503},{"EARLY_PHASE1":1504,"PHASE1":1506,"PHASE2":1508,"PHASE3":1510,"PHASE4":1516,"NA":1518},{"trials":1505,"activeCount":64},[],{"trials":1507,"activeCount":64},[],{"trials":1509,"activeCount":64},[],{"trials":1511,"activeCount":64},[1512],{"nctId":1468,"briefTitle":1469,"status":102,"phases":1513,"primaryCompletion":339,"completion":1385,"start":1471,"enrollment":1472,"conditions":1514,"interventions":1515},[54],[778],[1457,1475,1476,1477,1478,1479],{"trials":1517,"activeCount":64},[],{"trials":1519,"activeCount":64},[],{"intervention":1477,"totalTrials":133,"cells":1521},{"EARLY_PHASE1":1522,"PHASE1":1524,"PHASE2":1526,"PHASE3":1528,"PHASE4":1534,"NA":1536},{"trials":1523,"activeCount":64},[],{"trials":1525,"activeCount":64},[],{"trials":1527,"activeCount":64},[],{"trials":1529,"activeCount":64},[1530],{"nctId":1468,"briefTitle":1469,"status":102,"phases":1531,"primaryCompletion":339,"completion":1385,"start":1471,"enrollment":1472,"conditions":1532,"interventions":1533},[54],[778],[1457,1475,1476,1477,1478,1479],{"trials":1535,"activeCount":64},[],{"trials":1537,"activeCount":64},[],{"intervention":1478,"totalTrials":133,"cells":1539},{"EARLY_PHASE1":1540,"PHASE1":1542,"PHASE2":1544,"PHASE3":1546,"PHASE4":1552,"NA":1554},{"trials":1541,"activeCount":64},[],{"trials":1543,"activeCount":64},[],{"trials":1545,"activeCount":64},[],{"trials":1547,"activeCount":64},[1548],{"nctId":1468,"briefTitle":1469,"status":102,"phases":1549,"primaryCompletion":339,"completion":1385,"start":1471,"enrollment":1472,"conditions":1550,"interventions":1551},[54],[778],[1457,1475,1476,1477,1478,1479],{"trials":1553,"activeCount":64},[],{"trials":1555,"activeCount":64},[],{"intervention":1479,"totalTrials":133,"cells":1557},{"EARLY_PHASE1":1558,"PHASE1":1560,"PHASE2":1562,"PHASE3":1564,"PHASE4":1570,"NA":1572},{"trials":1559,"activeCount":64},[],{"trials":1561,"activeCount":64},[],{"trials":1563,"activeCount":64},[],{"trials":1565,"activeCount":64},[1566],{"nctId":1468,"briefTitle":1469,"status":102,"phases":1567,"primaryCompletion":339,"completion":1385,"start":1471,"enrollment":1472,"conditions":1568,"interventions":1569},[54],[778],[1457,1475,1476,1477,1478,1479],{"trials":1571,"activeCount":64},[],{"trials":1573,"activeCount":64},[],{"intervention":81,"totalTrials":310,"cells":1575},{"EARLY_PHASE1":1576,"PHASE1":1578,"PHASE2":1580,"PHASE3":1598,"PHASE4":1600,"NA":1602},{"trials":1577,"activeCount":64},[],{"trials":1579,"activeCount":64},[],{"trials":1581,"activeCount":64},[1582,1586,1590,1594],{"nctId":70,"briefTitle":71,"status":72,"phases":1583,"primaryCompletion":74,"completion":75,"start":76,"enrollment":77,"conditions":1584,"interventions":1585},[53],[79],[81,82,83,84,59,85],{"nctId":177,"briefTitle":178,"status":72,"phases":1587,"primaryCompletion":180,"completion":181,"start":182,"enrollment":183,"conditions":1588,"interventions":1589},[53],[185],[81,187,85,188,83],{"nctId":702,"briefTitle":703,"status":102,"phases":1591,"start":705,"enrollment":706,"conditions":1592,"interventions":1593},[53],[708],[710,711,712,129],{"nctId":772,"briefTitle":773,"status":102,"phases":1595,"completion":775,"start":776,"conditions":1596,"interventions":1597},[53],[778],[710,762],{"trials":1599,"activeCount":64},[],{"trials":1601,"activeCount":64},[],{"trials":1603,"activeCount":64},[],{"intervention":83,"totalTrials":310,"cells":1605},{"EARLY_PHASE1":1606,"PHASE1":1608,"PHASE2":1610,"PHASE3":1628,"PHASE4":1630,"NA":1632},{"trials":1607,"activeCount":64},[],{"trials":1609,"activeCount":64},[],{"trials":1611,"activeCount":64},[1612,1616,1620,1624],{"nctId":70,"briefTitle":71,"status":72,"phases":1613,"primaryCompletion":74,"completion":75,"start":76,"enrollment":77,"conditions":1614,"interventions":1615},[53],[79],[81,82,83,84,59,85],{"nctId":177,"briefTitle":178,"status":72,"phases":1617,"primaryCompletion":180,"completion":181,"start":182,"enrollment":183,"conditions":1618,"interventions":1619},[53],[185],[81,187,85,188,83],{"nctId":87,"briefTitle":88,"status":72,"phases":1621,"primaryCompletion":90,"completion":91,"start":92,"enrollment":93,"conditions":1622,"interventions":1623},[53],[33],[96,59,97,83,85,98],{"nctId":121,"briefTitle":122,"status":102,"phases":1625,"completion":124,"start":125,"enrollment":126,"conditions":1626,"interventions":1627},[53],[33],[129,130,131,132],{"trials":1629,"activeCount":64},[],{"trials":1631,"activeCount":64},[],{"trials":1633,"activeCount":64},[],{"intervention":1635,"totalTrials":133,"cells":1636},"Dornase Alfa",{"EARLY_PHASE1":1637,"PHASE1":1639,"PHASE2":1641,"PHASE3":1655,"PHASE4":1657,"NA":1659},{"trials":1638,"activeCount":64},[],{"trials":1640,"activeCount":64},[],{"trials":1642,"activeCount":64},[1643],{"nctId":1644,"briefTitle":1645,"status":72,"phases":1646,"primaryCompletion":1647,"completion":1648,"start":1649,"enrollment":1650,"conditions":1651,"interventions":1653},"NCT05880524","Reduction of SystemiC Inflammation After Ischemic Stroke by Intravenous DNase Administration (ReSCInD)",[53],"2025-12","2026-01","2024-12",36,[29,1652],"Inflammatory Response",[1635,1654],"Isotonic Saline Solution",{"trials":1656,"activeCount":64},[],{"trials":1658,"activeCount":64},[],{"trials":1660,"activeCount":64},[],{"intervention":1654,"totalTrials":133,"cells":1662},{"EARLY_PHASE1":1663,"PHASE1":1665,"PHASE2":1667,"PHASE3":1673,"PHASE4":1675,"NA":1677},{"trials":1664,"activeCount":64},[],{"trials":1666,"activeCount":64},[],{"trials":1668,"activeCount":64},[1669],{"nctId":1644,"briefTitle":1645,"status":72,"phases":1670,"primaryCompletion":1647,"completion":1648,"start":1649,"enrollment":1650,"conditions":1671,"interventions":1672},[53],[29,1652],[1635,1654],{"trials":1674,"activeCount":64},[],{"trials":1676,"activeCount":64},[],{"trials":1678,"activeCount":64},[],{"intervention":82,"totalTrials":133,"cells":1680},{"EARLY_PHASE1":1681,"PHASE1":1683,"PHASE2":1685,"PHASE3":1691,"PHASE4":1693,"NA":1695},{"trials":1682,"activeCount":64},[],{"trials":1684,"activeCount":64},[],{"trials":1686,"activeCount":64},[1687],{"nctId":70,"briefTitle":71,"status":72,"phases":1688,"primaryCompletion":74,"completion":75,"start":76,"enrollment":77,"conditions":1689,"interventions":1690},[53],[79],[81,82,83,84,59,85],{"trials":1692,"activeCount":64},[],{"trials":1694,"activeCount":64},[],{"trials":1696,"activeCount":64},[],{"intervention":1698,"totalTrials":133,"cells":1699},"Trabectedin",{"EARLY_PHASE1":1700,"PHASE1":1702,"PHASE2":1704,"PHASE3":1716,"PHASE4":1718,"NA":1720},{"trials":1701,"activeCount":64},[],{"trials":1703,"activeCount":64},[],{"trials":1705,"activeCount":64},[1706],{"nctId":1707,"briefTitle":1708,"status":72,"phases":1709,"primaryCompletion":1710,"completion":1710,"start":1711,"enrollment":117,"conditions":1712,"interventions":1714},"NCT02359474","Hyper-Thermia Enhanced Anti-tumor Efficacy of Trabectedin",[53],"2023-08","2014-12-19",[1713],"Sarcoma",[1698,1715],"DNA double-strand breaks",{"trials":1717,"activeCount":64},[],{"trials":1719,"activeCount":64},[],{"trials":1721,"activeCount":64},[],{"intervention":1715,"totalTrials":133,"cells":1723},{"EARLY_PHASE1":1724,"PHASE1":1726,"PHASE2":1728,"PHASE3":1734,"PHASE4":1736,"NA":1738},{"trials":1725,"activeCount":64},[],{"trials":1727,"activeCount":64},[],{"trials":1729,"activeCount":64},[1730],{"nctId":1707,"briefTitle":1708,"status":72,"phases":1731,"primaryCompletion":1710,"completion":1710,"start":1711,"enrollment":117,"conditions":1732,"interventions":1733},[53],[1713],[1698,1715],{"trials":1735,"activeCount":64},[],{"trials":1737,"activeCount":64},[],{"trials":1739,"activeCount":64},[],{"intervention":1741,"totalTrials":133,"cells":1742},"Navelbine",{"EARLY_PHASE1":1743,"PHASE1":1745,"PHASE2":1747,"PHASE3":1757,"PHASE4":1759,"NA":1761},{"trials":1744,"activeCount":64},[],{"trials":1746,"activeCount":64},[],{"trials":1748,"activeCount":64},[1749],{"nctId":1750,"briefTitle":1751,"status":102,"phases":1752,"conditions":1753,"interventions":1755},"NCT00433095","Vinorelbine (Oral) Plus Trastuzumab for 1st-line Treatment of HER2\u002FNeu Overexpressing Breast Cancer",[53],[1754],"Carcinoma Breast Stage IV",[1741,1756,1741],"Herceptin",{"trials":1758,"activeCount":64},[],{"trials":1760,"activeCount":64},[],{"trials":1762,"activeCount":64},[],{"intervention":1756,"totalTrials":133,"cells":1764},{"EARLY_PHASE1":1765,"PHASE1":1767,"PHASE2":1769,"PHASE3":1775,"PHASE4":1777,"NA":1779},{"trials":1766,"activeCount":64},[],{"trials":1768,"activeCount":64},[],{"trials":1770,"activeCount":64},[1771],{"nctId":1750,"briefTitle":1751,"status":102,"phases":1772,"conditions":1773,"interventions":1774},[53],[1754],[1741,1756,1741],{"trials":1776,"activeCount":64},[],{"trials":1778,"activeCount":64},[],{"trials":1780,"activeCount":64},[],{"intervention":187,"totalTrials":133,"cells":1782},{"EARLY_PHASE1":1783,"PHASE1":1785,"PHASE2":1787,"PHASE3":1793,"PHASE4":1795,"NA":1797},{"trials":1784,"activeCount":64},[],{"trials":1786,"activeCount":64},[],{"trials":1788,"activeCount":64},[1789],{"nctId":177,"briefTitle":178,"status":72,"phases":1790,"primaryCompletion":180,"completion":181,"start":182,"enrollment":183,"conditions":1791,"interventions":1792},[53],[185],[81,187,85,188,83],{"trials":1794,"activeCount":64},[],{"trials":1796,"activeCount":64},[],{"trials":1798,"activeCount":64},[],{"intervention":188,"totalTrials":133,"cells":1800},{"EARLY_PHASE1":1801,"PHASE1":1803,"PHASE2":1805,"PHASE3":1811,"PHASE4":1813,"NA":1815},{"trials":1802,"activeCount":64},[],{"trials":1804,"activeCount":64},[],{"trials":1806,"activeCount":64},[1807],{"nctId":177,"briefTitle":178,"status":72,"phases":1808,"primaryCompletion":180,"completion":181,"start":182,"enrollment":183,"conditions":1809,"interventions":1810},[53],[185],[81,187,85,188,83],{"trials":1812,"activeCount":64},[],{"trials":1814,"activeCount":64},[],{"trials":1816,"activeCount":64},[],{"intervention":1818,"totalTrials":133,"cells":1819},"Azacitidine",{"EARLY_PHASE1":1820,"PHASE1":1822,"PHASE2":1824,"PHASE3":1839,"PHASE4":1841,"NA":1843},{"trials":1821,"activeCount":64},[],{"trials":1823,"activeCount":64},[],{"trials":1825,"activeCount":64},[1826],{"nctId":1827,"briefTitle":1828,"status":72,"phases":1829,"primaryCompletion":1830,"completion":1831,"start":1832,"enrollment":1833,"conditions":1834,"interventions":1836},"NCT04913922","Relatlimab With Nivolumab and 5-Azacytidine for the Treatment of AML",[53],"2025-03","2026-03","2021-05-05",30,[1835],"Acute Myeloid Leukemia",[1818,1837,1838],"Nivolumab","Relatlimab",{"trials":1840,"activeCount":64},[],{"trials":1842,"activeCount":64},[],{"trials":1844,"activeCount":64},[],{"intervention":1837,"totalTrials":133,"cells":1846},{"EARLY_PHASE1":1847,"PHASE1":1849,"PHASE2":1851,"PHASE3":1857,"PHASE4":1859,"NA":1861},{"trials":1848,"activeCount":64},[],{"trials":1850,"activeCount":64},[],{"trials":1852,"activeCount":64},[1853],{"nctId":1827,"briefTitle":1828,"status":72,"phases":1854,"primaryCompletion":1830,"completion":1831,"start":1832,"enrollment":1833,"conditions":1855,"interventions":1856},[53],[1835],[1818,1837,1838],{"trials":1858,"activeCount":64},[],{"trials":1860,"activeCount":64},[],{"trials":1862,"activeCount":64},[],{"intervention":1838,"totalTrials":133,"cells":1864},{"EARLY_PHASE1":1865,"PHASE1":1867,"PHASE2":1869,"PHASE3":1875,"PHASE4":1877,"NA":1879},{"trials":1866,"activeCount":64},[],{"trials":1868,"activeCount":64},[],{"trials":1870,"activeCount":64},[1871],{"nctId":1827,"briefTitle":1828,"status":72,"phases":1872,"primaryCompletion":1830,"completion":1831,"start":1832,"enrollment":1833,"conditions":1873,"interventions":1874},[53],[1835],[1818,1837,1838],{"trials":1876,"activeCount":64},[],{"trials":1878,"activeCount":64},[],{"trials":1880,"activeCount":64},[],{"intervention":1882,"totalTrials":133,"cells":1883},"Ibrutinib",{"EARLY_PHASE1":1884,"PHASE1":1886,"PHASE2":1888,"PHASE3":1902,"PHASE4":1904,"NA":1906},{"trials":1885,"activeCount":64},[],{"trials":1887,"activeCount":64},[],{"trials":1889,"activeCount":64},[1890],{"nctId":1891,"briefTitle":1892,"status":72,"phases":1893,"primaryCompletion":1894,"completion":1895,"start":1896,"enrollment":1897,"conditions":1898,"interventions":1900},"NCT02689869","Combination of PCI-32765 With Obinutuzumab in Untreated Follicular Lymphoma",[53],"2022-04","2022-07","2016-04",98,[1899],"Indolent Non-Hodgkin Lymphoma",[1882,1901],"GA 101",{"trials":1903,"activeCount":64},[],{"trials":1905,"activeCount":64},[],{"trials":1907,"activeCount":64},[],{"intervention":1901,"totalTrials":133,"cells":1909},{"EARLY_PHASE1":1910,"PHASE1":1912,"PHASE2":1914,"PHASE3":1920,"PHASE4":1922,"NA":1924},{"trials":1911,"activeCount":64},[],{"trials":1913,"activeCount":64},[],{"trials":1915,"activeCount":64},[1916],{"nctId":1891,"briefTitle":1892,"status":72,"phases":1917,"primaryCompletion":1894,"completion":1895,"start":1896,"enrollment":1897,"conditions":1918,"interventions":1919},[53],[1899],[1882,1901],{"trials":1921,"activeCount":64},[],{"trials":1923,"activeCount":64},[],{"trials":1925,"activeCount":64},[],{"intervention":1927,"totalTrials":133,"cells":1928},"Niacin",{"EARLY_PHASE1":1929,"PHASE1":1931,"PHASE2":1933,"PHASE3":1944,"PHASE4":1946,"NA":1948},{"trials":1930,"activeCount":64},[],{"trials":1932,"activeCount":64},[],{"trials":1934,"activeCount":64},[1935],{"nctId":1936,"briefTitle":1937,"status":72,"phases":1938,"start":775,"enrollment":1939,"conditions":1940,"interventions":1942},"NCT00431145","Niacin As Secondary Prevention Of Coronary Artery Disease (NASPOCAD)",[53],80,[1941],"Coronary Artery Disease",[1927,1943],"Niacin+Statin",{"trials":1945,"activeCount":64},[],{"trials":1947,"activeCount":64},[],{"trials":1949,"activeCount":64},[],{"intervention":1943,"totalTrials":133,"cells":1951},{"EARLY_PHASE1":1952,"PHASE1":1954,"PHASE2":1956,"PHASE3":1962,"PHASE4":1964,"NA":1966},{"trials":1953,"activeCount":64},[],{"trials":1955,"activeCount":64},[],{"trials":1957,"activeCount":64},[1958],{"nctId":1936,"briefTitle":1937,"status":72,"phases":1959,"start":775,"enrollment":1939,"conditions":1960,"interventions":1961},[53],[1941],[1927,1943],{"trials":1963,"activeCount":64},[],{"trials":1965,"activeCount":64},[],{"trials":1967,"activeCount":64},[],{"intervention":111,"totalTrials":133,"cells":1969},{"EARLY_PHASE1":1970,"PHASE1":1972,"PHASE2":1974,"PHASE3":1980,"PHASE4":1982,"NA":1984},{"trials":1971,"activeCount":64},[],{"trials":1973,"activeCount":64},[],{"trials":1975,"activeCount":64},[1976],{"nctId":100,"briefTitle":101,"status":102,"phases":1977,"primaryCompletion":104,"completion":105,"start":106,"enrollment":107,"conditions":1978,"interventions":1979},[53],[109],[85,84,59,98,111],{"trials":1981,"activeCount":64},[],{"trials":1983,"activeCount":64},[],{"trials":1985,"activeCount":64},[],{"intervention":1987,"totalTrials":133,"cells":1988},"Blinatumomab in combination with donor lymphocyte",{"EARLY_PHASE1":1989,"PHASE1":1991,"PHASE2":1993,"PHASE3":2010,"PHASE4":2012,"NA":2014},{"trials":1990,"activeCount":64},[],{"trials":1992,"activeCount":64},[],{"trials":1994,"activeCount":64},[1995],{"nctId":1996,"briefTitle":1997,"status":1998,"phases":1999,"primaryCompletion":2000,"completion":2001,"start":2002,"enrollment":64,"conditions":2003,"interventions":2009},"NCT03982992","Allogeneic Donor Lymphocyte Infusions Combined With Blinatumomab","WITHDRAWN",[53],"2021-05-31","2021-11-30","2019-06-01",[2004,2005,2006,2007,2008],"B Cell Precursor Acute Lymphoblastic Leukemia With Mixed Chimerism or Minimal Residual Disease After Allogeneic Stem Cell Transplantation","B-Cell Acute Lymphoblastic Leukemia","Acute Lymphoblastic Leukemia","Acute Lymphoblastic Leukemia in Remission","Acute Lymphoblastic Leukemia, Adult",[1987],{"trials":2011,"activeCount":64},[],{"trials":2013,"activeCount":64},[],{"trials":2015,"activeCount":64},[],{"intervention":2017,"totalTrials":133,"cells":2018},"SOC chemotherapy",{"EARLY_PHASE1":2019,"PHASE1":2021,"PHASE2":2023,"PHASE3":2034,"PHASE4":2036,"NA":2038},{"trials":2020,"activeCount":64},[],{"trials":2022,"activeCount":64},[],{"trials":2024,"activeCount":64},[2025],{"nctId":2026,"briefTitle":2027,"status":392,"phases":2028,"primaryCompletion":2029,"completion":2029,"start":2030,"enrollment":22,"conditions":2031,"interventions":2033},"NCT05114213","MR-Guided Adaptive SBRT of Primary Tumor for Pain Control in Metastatic PDAC",[53],"2025-11-11","2021-12-15",[2032],"Pancreatic Cancer",[2017],{"trials":2035,"activeCount":64},[],{"trials":2037,"activeCount":64},[],{"trials":2039,"activeCount":64},[],{"intervention":2041,"totalTrials":133,"cells":2042},"Simvastatin",{"EARLY_PHASE1":2043,"PHASE1":2045,"PHASE2":2047,"PHASE3":2057,"PHASE4":2059,"NA":2061},{"trials":2044,"activeCount":64},[],{"trials":2046,"activeCount":64},[],{"trials":2048,"activeCount":64},[2049],{"nctId":2050,"briefTitle":2051,"status":102,"phases":2052,"completion":2053,"start":687,"enrollment":1833,"conditions":2054,"interventions":2056},"NCT00399867","Simvastatin as Inhibitor of Cell Adhesion Mediated Drug Resistance in Patients With Refractory Multiple Myeloma.",[53],"2007-04",[2055],"Multiple Myeloma",[2041],{"trials":2058,"activeCount":64},[],{"trials":2060,"activeCount":64},[],{"trials":2062,"activeCount":64},[],{"intervention":2064,"totalTrials":133,"cells":2065},"DC vaccination for postremission therapy in AML",{"EARLY_PHASE1":2066,"PHASE1":2068,"PHASE2":2070,"PHASE3":2082,"PHASE4":2084,"NA":2086},{"trials":2067,"activeCount":64},[],{"trials":2069,"activeCount":64},[],{"trials":2071,"activeCount":64},[2072],{"nctId":2073,"briefTitle":2074,"status":102,"phases":2075,"primaryCompletion":2076,"completion":2077,"start":2078,"enrollment":2079,"conditions":2080,"interventions":2081},"NCT01734304","DC Vaccination for Postremission Therapy in AML",[52,53],"2018-03-31","2018-09-30","2013-11-05",13,[1835],[2064],{"trials":2083,"activeCount":64},[],{"trials":2085,"activeCount":64},[],{"trials":2087,"activeCount":64},[],{"intervention":2089,"totalTrials":133,"cells":2090},"Pazopanib",{"EARLY_PHASE1":2091,"PHASE1":2093,"PHASE2":2095,"PHASE3":2105,"PHASE4":2107,"NA":2109},{"trials":2092,"activeCount":64},[],{"trials":2094,"activeCount":64},[],{"trials":2096,"activeCount":64},[2097],{"nctId":2098,"briefTitle":2099,"status":392,"phases":2100,"primaryCompletion":2101,"completion":2101,"start":2102,"enrollment":133,"conditions":2103,"interventions":2104},"NCT02207309","Pazopanib Maintenance Phase II",[53],"2016-07-29","2015-06-22",[1713],[2089],{"trials":2106,"activeCount":64},[],{"trials":2108,"activeCount":64},[],{"trials":2110,"activeCount":64},[],{"intervention":2112,"totalTrials":133,"cells":2113},"Copanlisib",{"EARLY_PHASE1":2114,"PHASE1":2116,"PHASE2":2118,"PHASE3":2131,"PHASE4":2133,"NA":2135},{"trials":2115,"activeCount":64},[],{"trials":2117,"activeCount":64},[],{"trials":2119,"activeCount":64},[2120],{"nctId":2121,"briefTitle":2122,"status":72,"phases":2123,"primaryCompletion":2124,"completion":2125,"start":2126,"enrollment":1897,"conditions":2127,"interventions":2129},"NCT05387616","A Prospective Multicenter Phase 2 Study of the Chemotherapy-Free Combination of the Intravenous Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Copanlisib in Combination With Obinutuzumab in Patients With Previously Untreated Follicular Lymphoma (FL) and a High Tumor Burden",[53],"2023-09-16","2026-05-19","2020-10-19",[2128],"Follicular Lymphoma",[2112,2130],"Obinutuzumab",{"trials":2132,"activeCount":64},[],{"trials":2134,"activeCount":64},[],{"trials":2136,"activeCount":64},[],{"intervention":2130,"totalTrials":133,"cells":2138},{"EARLY_PHASE1":2139,"PHASE1":2141,"PHASE2":2143,"PHASE3":2149,"PHASE4":2151,"NA":2153},{"trials":2140,"activeCount":64},[],{"trials":2142,"activeCount":64},[],{"trials":2144,"activeCount":64},[2145],{"nctId":2121,"briefTitle":2122,"status":72,"phases":2146,"primaryCompletion":2124,"completion":2125,"start":2126,"enrollment":1897,"conditions":2147,"interventions":2148},[53],[2128],[2112,2130],{"trials":2150,"activeCount":64},[],{"trials":2152,"activeCount":64},[],{"trials":2154,"activeCount":64},[],{"intervention":711,"totalTrials":133,"cells":2156},{"EARLY_PHASE1":2157,"PHASE1":2159,"PHASE2":2161,"PHASE3":2167,"PHASE4":2169,"NA":2171},{"trials":2158,"activeCount":64},[],{"trials":2160,"activeCount":64},[],{"trials":2162,"activeCount":64},[2163],{"nctId":702,"briefTitle":703,"status":102,"phases":2164,"start":705,"enrollment":706,"conditions":2165,"interventions":2166},[53],[708],[710,711,712,129],{"trials":2168,"activeCount":64},[],{"trials":2170,"activeCount":64},[],{"trials":2172,"activeCount":64},[],{"intervention":712,"totalTrials":133,"cells":2174},{"EARLY_PHASE1":2175,"PHASE1":2177,"PHASE2":2179,"PHASE3":2185,"PHASE4":2187,"NA":2189},{"trials":2176,"activeCount":64},[],{"trials":2178,"activeCount":64},[],{"trials":2180,"activeCount":64},[2181],{"nctId":702,"briefTitle":703,"status":102,"phases":2182,"start":705,"enrollment":706,"conditions":2183,"interventions":2184},[53],[708],[710,711,712,129],{"trials":2186,"activeCount":64},[],{"trials":2188,"activeCount":64},[],{"trials":2190,"activeCount":64},[],{"intervention":2192,"totalTrials":133,"cells":2193},"Docetaxel 50 mg\u002Fm2, 1-hour-Infusion, day 1",{"EARLY_PHASE1":2194,"PHASE1":2196,"PHASE2":2198,"PHASE3":2213,"PHASE4":2215,"NA":2217},{"trials":2195,"activeCount":64},[],{"trials":2197,"activeCount":64},[],{"trials":2199,"activeCount":64},[2200],{"nctId":2201,"briefTitle":2202,"status":72,"phases":2203,"primaryCompletion":394,"completion":2204,"start":2205,"enrollment":2206,"conditions":2207,"interventions":2209},"NCT01160419","Multicenter Study to Perioperative Chemotherapy for Resectable Adenocarcinoma in Gastric Cancer",[53],"2014-05","2009-12",49,[2208],"Gastric Cancer",[2192,2210,2211,2212],"Oxaliplatin 85 mg\u002Fm², 2-hour-Infusion, day 1","Folinic acid 200 mg\u002Fm², 1-2-hour-Infusion, day 1","5-FU 2600 mg\u002Fm², 24-hour-Infusion, day 1",{"trials":2214,"activeCount":64},[],{"trials":2216,"activeCount":64},[],{"trials":2218,"activeCount":64},[],{"intervention":2210,"totalTrials":133,"cells":2220},{"EARLY_PHASE1":2221,"PHASE1":2223,"PHASE2":2225,"PHASE3":2231,"PHASE4":2233,"NA":2235},{"trials":2222,"activeCount":64},[],{"trials":2224,"activeCount":64},[],{"trials":2226,"activeCount":64},[2227],{"nctId":2201,"briefTitle":2202,"status":72,"phases":2228,"primaryCompletion":394,"completion":2204,"start":2205,"enrollment":2206,"conditions":2229,"interventions":2230},[53],[2208],[2192,2210,2211,2212],{"trials":2232,"activeCount":64},[],{"trials":2234,"activeCount":64},[],{"trials":2236,"activeCount":64},[],{"intervention":2211,"totalTrials":133,"cells":2238},{"EARLY_PHASE1":2239,"PHASE1":2241,"PHASE2":2243,"PHASE3":2249,"PHASE4":2251,"NA":2253},{"trials":2240,"activeCount":64},[],{"trials":2242,"activeCount":64},[],{"trials":2244,"activeCount":64},[2245],{"nctId":2201,"briefTitle":2202,"status":72,"phases":2246,"primaryCompletion":394,"completion":2204,"start":2205,"enrollment":2206,"conditions":2247,"interventions":2248},[53],[2208],[2192,2210,2211,2212],{"trials":2250,"activeCount":64},[],{"trials":2252,"activeCount":64},[],{"trials":2254,"activeCount":64},[],{"intervention":2212,"totalTrials":133,"cells":2256},{"EARLY_PHASE1":2257,"PHASE1":2259,"PHASE2":2261,"PHASE3":2267,"PHASE4":2269,"NA":2271},{"trials":2258,"activeCount":64},[],{"trials":2260,"activeCount":64},[],{"trials":2262,"activeCount":64},[2263],{"nctId":2201,"briefTitle":2202,"status":72,"phases":2264,"primaryCompletion":394,"completion":2204,"start":2205,"enrollment":2206,"conditions":2265,"interventions":2266},[53],[2208],[2192,2210,2211,2212],{"trials":2268,"activeCount":64},[],{"trials":2270,"activeCount":64},[],{"trials":2272,"activeCount":64},[],{"intervention":2274,"totalTrials":133,"cells":2275},"Delta9-Tetrahydrocannabinol",{"EARLY_PHASE1":2276,"PHASE1":2278,"PHASE2":2280,"PHASE3":2291,"PHASE4":2293,"NA":2295},{"trials":2277,"activeCount":64},[],{"trials":2279,"activeCount":64},[],{"trials":2281,"activeCount":64},[2282],{"nctId":2283,"briefTitle":2284,"status":72,"phases":2285,"completion":360,"start":663,"enrollment":2286,"conditions":2287,"interventions":2290},"NCT00377468","Effect of Delta-9-Tetrahydrocannabinol on the Prevention of Chronic Pain in Patients With Acute CRPS (ETIC-Study)",[53],100,[2288,2289],"Complex Regional Pain Syndromes","CRPS",[2274],{"trials":2292,"activeCount":64},[],{"trials":2294,"activeCount":64},[],{"trials":2296,"activeCount":64},[],{"intervention":2298,"totalTrials":133,"cells":2299},"adenosine",{"EARLY_PHASE1":2300,"PHASE1":2302,"PHASE2":2304,"PHASE3":2313,"PHASE4":2315,"NA":2317},{"trials":2301,"activeCount":64},[],{"trials":2303,"activeCount":64},[],{"trials":2305,"activeCount":64},[2306],{"nctId":2307,"briefTitle":2308,"status":72,"phases":2309,"conditions":2310,"interventions":2312},"NCT00845689","Prevention of Liver Damage During Liver Surgery",[52,53],[2311],"Liver Tumors",[2298,2298],{"trials":2314,"activeCount":64},[],{"trials":2316,"activeCount":64},[],{"trials":2318,"activeCount":64},[],{"intervention":367,"totalTrials":350,"cells":2320},{"EARLY_PHASE1":2321,"PHASE1":2323,"PHASE2":2352,"PHASE3":2354,"PHASE4":2356,"NA":2358},{"trials":2322,"activeCount":64},[],{"trials":2324,"activeCount":64},[2325,2336,2348],{"nctId":2326,"briefTitle":2327,"status":102,"phases":2328,"primaryCompletion":2329,"completion":362,"start":2330,"enrollment":16,"conditions":2331,"interventions":2334},"NCT00980083","GLP-1 - Regulatory Mechanism of Postprandial Glycemia",[52],"2005-07","2004-10",[2332,2333],"Healthy Subjects","Gastric Emptying",[367,2335],"Exendin(9-39)amide",{"nctId":2337,"briefTitle":2338,"status":102,"phases":2339,"primaryCompletion":2340,"completion":2341,"start":2342,"enrollment":363,"conditions":2343,"interventions":2345},"NCT01449019","The Role of Endogenous Glucagon-like Peptide 1 (GLP-1) in Type 2 Diabetes Mellitus (T2DM)",[52],"2007-08","2010-07","2006-12",[2344],"Diabetes Mellitus, Type 2",[2346,2347],"exendin(9-39)amide","saline",{"nctId":357,"briefTitle":358,"status":102,"phases":2349,"primaryCompletion":360,"completion":361,"start":362,"enrollment":363,"conditions":2350,"interventions":2351},[52],[365],[349,367,368],{"trials":2353,"activeCount":64},[],{"trials":2355,"activeCount":64},[],{"trials":2357,"activeCount":64},[],{"trials":2359,"activeCount":64},[],{"intervention":2346,"totalTrials":350,"cells":2361},{"EARLY_PHASE1":2362,"PHASE1":2364,"PHASE2":2388,"PHASE3":2390,"PHASE4":2392,"NA":2394},{"trials":2363,"activeCount":64},[],{"trials":2365,"activeCount":64},[2366,2370,2374],{"nctId":2326,"briefTitle":2327,"status":102,"phases":2367,"primaryCompletion":2329,"completion":362,"start":2330,"enrollment":16,"conditions":2368,"interventions":2369},[52],[2332,2333],[367,2335],{"nctId":2337,"briefTitle":2338,"status":102,"phases":2371,"primaryCompletion":2340,"completion":2341,"start":2342,"enrollment":363,"conditions":2372,"interventions":2373},[52],[2344],[2346,2347],{"nctId":2375,"briefTitle":2376,"status":102,"phases":2377,"completion":2378,"start":2379,"enrollment":19,"conditions":2380,"interventions":2386},"NCT00468091","Effects of Exendin(9-39) on Gastroduodenal Motility",[52],"2000-09","1999-02",[2381,2382,2383,2384,2385],"Digestive Physiology","Gastrointestinal Motility","Gastrointestinal Hormones","Glucagon-like Peptide 1","Exendin (9-39)",[2346,2387],"atropine",{"trials":2389,"activeCount":64},[],{"trials":2391,"activeCount":64},[],{"trials":2393,"activeCount":64},[],{"trials":2395,"activeCount":64},[],{"intervention":2397,"totalTrials":133,"cells":2398},"flupirtine",{"EARLY_PHASE1":2399,"PHASE1":2401,"PHASE2":2411,"PHASE3":2413,"PHASE4":2415,"NA":2417},{"trials":2400,"activeCount":64},[],{"trials":2402,"activeCount":64},[2403],{"nctId":2404,"briefTitle":2405,"status":102,"phases":2406,"primaryCompletion":2341,"completion":2407,"start":1359,"enrollment":664,"conditions":2408,"interventions":2410},"NCT01450865","Effect of the Kv7-channel Opener Flupirtine on the Excitability of Human Peripheral Myelinated Axons in Vivo",[52],"2010-08",[2409,1023],"Axonal Change, Neuronal",[2397],{"trials":2412,"activeCount":64},[],{"trials":2414,"activeCount":64},[],{"trials":2416,"activeCount":64},[],{"trials":2418,"activeCount":64},[],{"intervention":2387,"totalTrials":133,"cells":2420},{"EARLY_PHASE1":2421,"PHASE1":2423,"PHASE2":2429,"PHASE3":2431,"PHASE4":2433,"NA":2435},{"trials":2422,"activeCount":64},[],{"trials":2424,"activeCount":64},[2425],{"nctId":2375,"briefTitle":2376,"status":102,"phases":2426,"completion":2378,"start":2379,"enrollment":19,"conditions":2427,"interventions":2428},[52],[2381,2382,2383,2384,2385],[2346,2387],{"trials":2430,"activeCount":64},[],{"trials":2432,"activeCount":64},[],{"trials":2434,"activeCount":64},[],{"trials":2436,"activeCount":64},[],{"intervention":2438,"totalTrials":133,"cells":2439},"GLP-1 control",{"EARLY_PHASE1":2440,"PHASE1":2442,"PHASE2":2457,"PHASE3":2459,"PHASE4":2461,"NA":2463},{"trials":2441,"activeCount":64},[],{"trials":2443,"activeCount":64},[2444],{"nctId":2445,"briefTitle":2446,"status":102,"phases":2447,"completion":2448,"start":124,"enrollment":11,"conditions":2449,"interventions":2451},"NCT00393445","Exendin(9-39)Amide as a Glucagon-like Peptide-1 (GLP-1) Receptor Antagonist in Humans",[52],"2007-05",[2450],"Hyperglycemia",[2438,2452,2453,2454,2455,2456],"GLP-1 and Exendin(9-39) 300","saline control","GLP-1 and Exendin(9-39) 600","GLP-1 and Exendin(9-39) 900","GLP-1 and Exendin(9-39) 1200",{"trials":2458,"activeCount":64},[],{"trials":2460,"activeCount":64},[],{"trials":2462,"activeCount":64},[],{"trials":2464,"activeCount":64},[],{"intervention":2452,"totalTrials":133,"cells":2466},{"EARLY_PHASE1":2467,"PHASE1":2469,"PHASE2":2475,"PHASE3":2477,"PHASE4":2479,"NA":2481},{"trials":2468,"activeCount":64},[],{"trials":2470,"activeCount":64},[2471],{"nctId":2445,"briefTitle":2446,"status":102,"phases":2472,"completion":2448,"start":124,"enrollment":11,"conditions":2473,"interventions":2474},[52],[2450],[2438,2452,2453,2454,2455,2456],{"trials":2476,"activeCount":64},[],{"trials":2478,"activeCount":64},[],{"trials":2480,"activeCount":64},[],{"trials":2482,"activeCount":64},[],{"intervention":2453,"totalTrials":133,"cells":2484},{"EARLY_PHASE1":2485,"PHASE1":2487,"PHASE2":2493,"PHASE3":2495,"PHASE4":2497,"NA":2499},{"trials":2486,"activeCount":64},[],{"trials":2488,"activeCount":64},[2489],{"nctId":2445,"briefTitle":2446,"status":102,"phases":2490,"completion":2448,"start":124,"enrollment":11,"conditions":2491,"interventions":2492},[52],[2450],[2438,2452,2453,2454,2455,2456],{"trials":2494,"activeCount":64},[],{"trials":2496,"activeCount":64},[],{"trials":2498,"activeCount":64},[],{"trials":2500,"activeCount":64},[],{"intervention":2454,"totalTrials":133,"cells":2502},{"EARLY_PHASE1":2503,"PHASE1":2505,"PHASE2":2511,"PHASE3":2513,"PHASE4":2515,"NA":2517},{"trials":2504,"activeCount":64},[],{"trials":2506,"activeCount":64},[2507],{"nctId":2445,"briefTitle":2446,"status":102,"phases":2508,"completion":2448,"start":124,"enrollment":11,"conditions":2509,"interventions":2510},[52],[2450],[2438,2452,2453,2454,2455,2456],{"trials":2512,"activeCount":64},[],{"trials":2514,"activeCount":64},[],{"trials":2516,"activeCount":64},[],{"trials":2518,"activeCount":64},[],{"intervention":2455,"totalTrials":133,"cells":2520},{"EARLY_PHASE1":2521,"PHASE1":2523,"PHASE2":2529,"PHASE3":2531,"PHASE4":2533,"NA":2535},{"trials":2522,"activeCount":64},[],{"trials":2524,"activeCount":64},[2525],{"nctId":2445,"briefTitle":2446,"status":102,"phases":2526,"completion":2448,"start":124,"enrollment":11,"conditions":2527,"interventions":2528},[52],[2450],[2438,2452,2453,2454,2455,2456],{"trials":2530,"activeCount":64},[],{"trials":2532,"activeCount":64},[],{"trials":2534,"activeCount":64},[],{"trials":2536,"activeCount":64},[],{"intervention":2456,"totalTrials":133,"cells":2538},{"EARLY_PHASE1":2539,"PHASE1":2541,"PHASE2":2547,"PHASE3":2549,"PHASE4":2551,"NA":2553},{"trials":2540,"activeCount":64},[],{"trials":2542,"activeCount":64},[2543],{"nctId":2445,"briefTitle":2446,"status":102,"phases":2544,"completion":2448,"start":124,"enrollment":11,"conditions":2545,"interventions":2546},[52],[2450],[2438,2452,2453,2454,2455,2456],{"trials":2548,"activeCount":64},[],{"trials":2550,"activeCount":64},[],{"trials":2552,"activeCount":64},[],{"trials":2554,"activeCount":64},[],{"intervention":368,"totalTrials":133,"cells":2556},{"EARLY_PHASE1":2557,"PHASE1":2559,"PHASE2":2565,"PHASE3":2567,"PHASE4":2569,"NA":2571},{"trials":2558,"activeCount":64},[],{"trials":2560,"activeCount":64},[2561],{"nctId":357,"briefTitle":358,"status":102,"phases":2562,"primaryCompletion":360,"completion":361,"start":362,"enrollment":363,"conditions":2563,"interventions":2564},[52],[365],[349,367,368],{"trials":2566,"activeCount":64},[],{"trials":2568,"activeCount":64},[],{"trials":2570,"activeCount":64},[],{"trials":2572,"activeCount":64},[],{"intervention":2574,"totalTrials":133,"cells":2575},"Betahistine dihydrochloride",{"EARLY_PHASE1":2576,"PHASE1":2578,"PHASE2":2591,"PHASE3":2593,"PHASE4":2595,"NA":2597},{"trials":2577,"activeCount":64},[],{"trials":2579,"activeCount":64},[2580],{"nctId":2581,"briefTitle":2582,"status":102,"phases":2583,"primaryCompletion":2584,"completion":2584,"start":2585,"enrollment":2586,"conditions":2587,"interventions":2589},"NCT05938517","Pharmacokinetic Profile of Betahistine With and Without Selegiline in Healthy Volunteers",[52],"2021-10-14","2021-06-02",15,[2588],"Ménière's Disease",[2574,2590],"Selegiline-hydrochloride",{"trials":2592,"activeCount":64},[],{"trials":2594,"activeCount":64},[],{"trials":2596,"activeCount":64},[],{"trials":2598,"activeCount":64},[],{"intervention":2590,"totalTrials":133,"cells":2600},{"EARLY_PHASE1":2601,"PHASE1":2603,"PHASE2":2609,"PHASE3":2611,"PHASE4":2613,"NA":2615},{"trials":2602,"activeCount":64},[],{"trials":2604,"activeCount":64},[2605],{"nctId":2581,"briefTitle":2582,"status":102,"phases":2606,"primaryCompletion":2584,"completion":2584,"start":2585,"enrollment":2586,"conditions":2607,"interventions":2608},[52],[2588],[2574,2590],{"trials":2610,"activeCount":64},[],{"trials":2612,"activeCount":64},[],{"trials":2614,"activeCount":64},[],{"trials":2616,"activeCount":64},[],{"intervention":2618,"totalTrials":133,"cells":2619},"Low dose Hydrocortisone",{"EARLY_PHASE1":2620,"PHASE1":2630,"PHASE2":2632,"PHASE3":2634,"PHASE4":2636,"NA":2638},{"trials":2621,"activeCount":64},[2622],{"nctId":2623,"briefTitle":2624,"status":102,"phases":2625,"primaryCompletion":2448,"completion":422,"start":2626,"enrollment":1833,"conditions":2627,"interventions":2629},"NCT00236925","Efficacy Study of Low-Dose Hydrocortisone Treatment for Fibromyalgia",[51],"2003-05",[2628],"Fibromyalgia",[2618],{"trials":2631,"activeCount":64},[],{"trials":2633,"activeCount":64},[],{"trials":2635,"activeCount":64},[],{"trials":2637,"activeCount":64},[],{"trials":2639,"activeCount":64},[],{"intervention":2641,"totalTrials":133,"cells":2642},"Neu-P11",{"EARLY_PHASE1":2643,"PHASE1":2645,"PHASE2":2647,"PHASE3":2649,"PHASE4":2651,"NA":2653},{"trials":2644,"activeCount":64},[],{"trials":2646,"activeCount":64},[],{"trials":2648,"activeCount":64},[],{"trials":2650,"activeCount":64},[],{"trials":2652,"activeCount":64},[],{"trials":2654,"activeCount":64},[2655],{"nctId":2656,"briefTitle":2657,"status":102,"phases":2658,"primaryCompletion":2659,"completion":2660,"start":339,"enrollment":2661,"conditions":2662,"interventions":2664},"NCT01558284","The Effect of Neu-P11 on Symptoms in Patients With D-IBS",[],"2014-01","2014-02",40,[2663],"Diarrhea- Irritable Bowel Syndrome",[2641],{"intervention":2666,"totalTrials":133,"cells":2667},"General anesthesia with propofol",{"EARLY_PHASE1":2668,"PHASE1":2670,"PHASE2":2672,"PHASE3":2674,"PHASE4":2676,"NA":2678},{"trials":2669,"activeCount":64},[],{"trials":2671,"activeCount":64},[],{"trials":2673,"activeCount":64},[],{"trials":2675,"activeCount":64},[],{"trials":2677,"activeCount":64},[],{"trials":2679,"activeCount":64},[2680],{"nctId":2681,"briefTitle":2682,"status":102,"phases":2683,"primaryCompletion":2684,"completion":2684,"start":2685,"enrollment":1833,"conditions":2686,"interventions":2688},"NCT01892683","Breath Monitoring of Propofol (Observational Study)",[],"2013-08","2013-05",[2687],"Anesthesia",[2666],{"intervention":2690,"totalTrials":133,"cells":2691},"oxytocin, placebo",{"EARLY_PHASE1":2692,"PHASE1":2694,"PHASE2":2696,"PHASE3":2698,"PHASE4":2700,"NA":2702},{"trials":2693,"activeCount":64},[],{"trials":2695,"activeCount":64},[],{"trials":2697,"activeCount":64},[],{"trials":2699,"activeCount":64},[],{"trials":2701,"activeCount":64},[],{"trials":2703,"activeCount":64},[2704],{"nctId":2705,"briefTitle":2706,"status":102,"phases":2707,"primaryCompletion":508,"completion":508,"start":2626,"enrollment":2708,"conditions":2709,"interventions":2711},"NCT00805662","Nasal Oxcytocin During IUI",[56],86,[2710],"Idiopathic Infertility",[2690],{"intervention":2713,"totalTrials":133,"cells":2714},"Histaminum hydrochloricum globuli",{"EARLY_PHASE1":2715,"PHASE1":2717,"PHASE2":2719,"PHASE3":2721,"PHASE4":2723,"NA":2725},{"trials":2716,"activeCount":64},[],{"trials":2718,"activeCount":64},[],{"trials":2720,"activeCount":64},[],{"trials":2722,"activeCount":64},[],{"trials":2724,"activeCount":64},[],{"trials":2726,"activeCount":64},[2727],{"nctId":2728,"briefTitle":2729,"status":102,"phases":2730,"primaryCompletion":2731,"completion":2731,"start":2732,"enrollment":2733,"conditions":2734,"interventions":2736},"NCT00937196","Placebo Effects on Blood Pressure Induced by Expectancy Manipulation",[56],"2007-03","2006-08",45,[2735],"Blood Pressure",[2713],{"intervention":2738,"totalTrials":133,"cells":2739},"40ml of Ropivacaine 0.5% Injectable Solution",{"EARLY_PHASE1":2740,"PHASE1":2742,"PHASE2":2744,"PHASE3":2746,"PHASE4":2748,"NA":2750},{"trials":2741,"activeCount":64},[],{"trials":2743,"activeCount":64},[],{"trials":2745,"activeCount":64},[],{"trials":2747,"activeCount":64},[],{"trials":2749,"activeCount":64},[],{"trials":2751,"activeCount":64},[2752],{"nctId":2753,"briefTitle":2754,"status":72,"phases":2755,"primaryCompletion":2756,"completion":2757,"start":2758,"enrollment":1074,"conditions":2759,"interventions":2762},"NCT04292691","High Ankle Block in Ankle Fractures",[56],"2021-04-01","2021-08-01","2020-04-01",[2760,2761],"Ankle Fractures","Anesthesia, Local",[2738,2763],"40ml of Ringer's Lactate",{"intervention":2763,"totalTrials":133,"cells":2765},{"EARLY_PHASE1":2766,"PHASE1":2768,"PHASE2":2770,"PHASE3":2772,"PHASE4":2774,"NA":2776},{"trials":2767,"activeCount":64},[],{"trials":2769,"activeCount":64},[],{"trials":2771,"activeCount":64},[],{"trials":2773,"activeCount":64},[],{"trials":2775,"activeCount":64},[],{"trials":2777,"activeCount":64},[2778],{"nctId":2753,"briefTitle":2754,"status":72,"phases":2779,"primaryCompletion":2756,"completion":2757,"start":2758,"enrollment":1074,"conditions":2780,"interventions":2781},[56],[2760,2761],[2738,2763],{"intervention":2783,"totalTrials":133,"cells":2784},"Sevoflurane",{"EARLY_PHASE1":2785,"PHASE1":2787,"PHASE2":2789,"PHASE3":2791,"PHASE4":2793,"NA":2795},{"trials":2786,"activeCount":64},[],{"trials":2788,"activeCount":64},[],{"trials":2790,"activeCount":64},[],{"trials":2792,"activeCount":64},[],{"trials":2794,"activeCount":64},[],{"trials":2796,"activeCount":64},[2797],{"nctId":2798,"briefTitle":2799,"status":72,"phases":2800,"completion":2801,"start":705,"enrollment":2802,"conditions":2803,"interventions":2805},"NCT00434382","Neuronal Mechanisms of Sensory Processing During General Anesthesia",[56],"2003-12",768,[2804],"General Anesthesia",[2783,2806,2807,2808,2809,2810,2811,2812],"Isoflurane","Desflurane","Propofol","Fentanyl","Sufentanil","Alfentanil","Remifentanil",{"intervention":2806,"totalTrials":133,"cells":2814},{"EARLY_PHASE1":2815,"PHASE1":2817,"PHASE2":2819,"PHASE3":2821,"PHASE4":2823,"NA":2825},{"trials":2816,"activeCount":64},[],{"trials":2818,"activeCount":64},[],{"trials":2820,"activeCount":64},[],{"trials":2822,"activeCount":64},[],{"trials":2824,"activeCount":64},[],{"trials":2826,"activeCount":64},[2827],{"nctId":2798,"briefTitle":2799,"status":72,"phases":2828,"completion":2801,"start":705,"enrollment":2802,"conditions":2829,"interventions":2830},[56],[2804],[2783,2806,2807,2808,2809,2810,2811,2812],{"intervention":2807,"totalTrials":133,"cells":2832},{"EARLY_PHASE1":2833,"PHASE1":2835,"PHASE2":2837,"PHASE3":2839,"PHASE4":2841,"NA":2843},{"trials":2834,"activeCount":64},[],{"trials":2836,"activeCount":64},[],{"trials":2838,"activeCount":64},[],{"trials":2840,"activeCount":64},[],{"trials":2842,"activeCount":64},[],{"trials":2844,"activeCount":64},[2845],{"nctId":2798,"briefTitle":2799,"status":72,"phases":2846,"completion":2801,"start":705,"enrollment":2802,"conditions":2847,"interventions":2848},[56],[2804],[2783,2806,2807,2808,2809,2810,2811,2812],{"intervention":2808,"totalTrials":133,"cells":2850},{"EARLY_PHASE1":2851,"PHASE1":2853,"PHASE2":2855,"PHASE3":2857,"PHASE4":2859,"NA":2861},{"trials":2852,"activeCount":64},[],{"trials":2854,"activeCount":64},[],{"trials":2856,"activeCount":64},[],{"trials":2858,"activeCount":64},[],{"trials":2860,"activeCount":64},[],{"trials":2862,"activeCount":64},[2863],{"nctId":2798,"briefTitle":2799,"status":72,"phases":2864,"completion":2801,"start":705,"enrollment":2802,"conditions":2865,"interventions":2866},[56],[2804],[2783,2806,2807,2808,2809,2810,2811,2812],{"intervention":2809,"totalTrials":133,"cells":2868},{"EARLY_PHASE1":2869,"PHASE1":2871,"PHASE2":2873,"PHASE3":2875,"PHASE4":2877,"NA":2879},{"trials":2870,"activeCount":64},[],{"trials":2872,"activeCount":64},[],{"trials":2874,"activeCount":64},[],{"trials":2876,"activeCount":64},[],{"trials":2878,"activeCount":64},[],{"trials":2880,"activeCount":64},[2881],{"nctId":2798,"briefTitle":2799,"status":72,"phases":2882,"completion":2801,"start":705,"enrollment":2802,"conditions":2883,"interventions":2884},[56],[2804],[2783,2806,2807,2808,2809,2810,2811,2812],{"intervention":2810,"totalTrials":133,"cells":2886},{"EARLY_PHASE1":2887,"PHASE1":2889,"PHASE2":2891,"PHASE3":2893,"PHASE4":2895,"NA":2897},{"trials":2888,"activeCount":64},[],{"trials":2890,"activeCount":64},[],{"trials":2892,"activeCount":64},[],{"trials":2894,"activeCount":64},[],{"trials":2896,"activeCount":64},[],{"trials":2898,"activeCount":64},[2899],{"nctId":2798,"briefTitle":2799,"status":72,"phases":2900,"completion":2801,"start":705,"enrollment":2802,"conditions":2901,"interventions":2902},[56],[2804],[2783,2806,2807,2808,2809,2810,2811,2812],{"intervention":2811,"totalTrials":133,"cells":2904},{"EARLY_PHASE1":2905,"PHASE1":2907,"PHASE2":2909,"PHASE3":2911,"PHASE4":2913,"NA":2915},{"trials":2906,"activeCount":64},[],{"trials":2908,"activeCount":64},[],{"trials":2910,"activeCount":64},[],{"trials":2912,"activeCount":64},[],{"trials":2914,"activeCount":64},[],{"trials":2916,"activeCount":64},[2917],{"nctId":2798,"briefTitle":2799,"status":72,"phases":2918,"completion":2801,"start":705,"enrollment":2802,"conditions":2919,"interventions":2920},[56],[2804],[2783,2806,2807,2808,2809,2810,2811,2812],{"intervention":2812,"totalTrials":133,"cells":2922},{"EARLY_PHASE1":2923,"PHASE1":2925,"PHASE2":2927,"PHASE3":2929,"PHASE4":2931,"NA":2933},{"trials":2924,"activeCount":64},[],{"trials":2926,"activeCount":64},[],{"trials":2928,"activeCount":64},[],{"trials":2930,"activeCount":64},[],{"trials":2932,"activeCount":64},[],{"trials":2934,"activeCount":64},[2935],{"nctId":2798,"briefTitle":2799,"status":72,"phases":2936,"completion":2801,"start":705,"enrollment":2802,"conditions":2937,"interventions":2938},[56],[2804],[2783,2806,2807,2808,2809,2810,2811,2812],{"intervention":2940,"totalTrials":133,"cells":2941},"Ozurdex",{"EARLY_PHASE1":2942,"PHASE1":2944,"PHASE2":2946,"PHASE3":2948,"PHASE4":2950,"NA":2952},{"trials":2943,"activeCount":64},[],{"trials":2945,"activeCount":64},[],{"trials":2947,"activeCount":64},[],{"trials":2949,"activeCount":64},[],{"trials":2951,"activeCount":64},[],{"trials":2953,"activeCount":64},[2954],{"nctId":2955,"briefTitle":2956,"status":102,"phases":2957,"primaryCompletion":378,"completion":447,"start":2958,"enrollment":2959,"conditions":2960,"interventions":2962},"NCT01945892","Dexamethasone-Implant for the Treatment of Macula Edema Due to Irvine Gass Syndrome",[],"2011-11",23,[1229,2961],"Visual Acuity",[2940],{"intervention":2964,"totalTrials":133,"cells":2965},"pramlintide",{"EARLY_PHASE1":2966,"PHASE1":2968,"PHASE2":2970,"PHASE3":2972,"PHASE4":2974,"NA":2976},{"trials":2967,"activeCount":64},[],{"trials":2969,"activeCount":64},[],{"trials":2971,"activeCount":64},[],{"trials":2973,"activeCount":64},[],{"trials":2975,"activeCount":64},[],{"trials":2977,"activeCount":64},[2978],{"nctId":2979,"briefTitle":2980,"status":102,"phases":2981,"primaryCompletion":2731,"completion":2053,"start":2982,"enrollment":2983,"conditions":2984,"interventions":2986},"NCT00489645","Effect of Hyperglycemia on Gastric Emptying Interactions With Pramlintide",[56],"2005-01",27,[2985],"Type 1 Diabetes",[2964,2964]]